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Macrophages can adopt an anti-inflammatory phenotype through exposure to TLR 
ligands together with immune complexes (IC). However, a thorough investigation of 
this phenotype in human macrophages has not yet been performed. In this work, we 
sought to characterize IC-induced regulatory activation in primary human macrophages 
(R-Mφ-IC). Analysis of the transcriptome and secretome revealed broad suppression 
of inflammatory molecules, and an upregulation of molecules involved in angiogenesis 
and the resolution of inflammation. RNAscope and flow cytometry analysis identified 
MMP-10 and DC-STAMP, among others, as potential biomarkers for this activation 
state. Pathway analysis predicted the activation of the Akt and ERK signaling 
pathways, which further studies confirmed were activated in these cells. Inhibition of 
  
Akt and ERK led to a suppression of R-Mφ-IC gene transcription, with Akt inhibition 
having a greater effect. Since GSK3 is a direct substrate of Akt, activation of this kinase 
was also investigated. The addition of IC to cells stimulated with lipopolysaccharide 
(LPS) significantly prevented the entry of GSK3 into the nucleus, while small-molecule 
inhibition of GSK3 phenocopied IC co-stimulation. To determine if GSK3 inhibition 
had anti-inflammatory activity, mice were injected intraperitoneally with macrophages 
treated with LPS and GSK3β-specific inhibitor. Compared to mice injected with 
macrophages stimulated only with LPS, the mice in the test group were slightly 
protected from lethal endotoxemia, but these results were not statistically significant 
(p-value = 0.063). Together these data are consistent with an anti-inflammatory role for 
Fc receptor cross-linking, and highlight the importance of the Akt/GSK3 signaling 
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Chapter 1: Introduction 
1.1 Innate Immunity 
Innate immunity refers to the non-adaptive branch of the immune system and 
broadly refers to any cell, tissue or fluid in the body that serves to defend the host 
against foreign organisms, and that does not have an adaptive component1. This 
therefore includes anatomical barriers such as skin, tears and mucous, and digestive 
enzymes, as well non-cellular systems such as inorganic chemicals and the complement 
cascade. It is thought that this system developed earlier in our evolutionary history than 
did the adaptive arm of the immune system, as it is present in most invertebrates, 
whereas the adaptive response is mainly expressed in higher vertebrate species2. The 
cells that make up the innate immune system include neutrophils, dendritic cells, 
macrophages, mast cells, eosinophils, basophils and NK cells. These cells are important 
in initiating inflammation, and are equipped with an array of pattern recognition 
receptors that recognize danger signals in order to activate an appropriate immune 
response3. Although these receptors are able to detect a wide variety of pathogen-
associated molecular patterns (PAMPs)4, this system is unable to develop memory or 
specificity for particular antigens. It has the advantage of triggering a rapid response 
that includes cytokine production, recruitment of other immune cells, destruction of 
pathogens, and antigen presentation to T cells5, the latter of which makes innate 







Macrophages are phagocytic white blood cells of the innate immune system 
that have a heightened capacity for digestion. These cells were first discovered in 1884 
by Russian zoologist Élie Metchnikoff, who won the Nobel Prize in 1908 for his 
contribution to the understanding of immunity6. They are ubiquitous in the body in a 
resting state, and are known for taking on specialized roles depending on which tissue 
they inhabit7. Beyond the clearance of dead cells and tissue debris8, macrophages are 
sentinel cells that can activate an immune response upon exposure to pathogens. 
Macrophages demonstrate a remarkable level of tissue diversity and an impressive 
ability to produce cytokines and other secreted factors in response to environmental 
cues. They are activated through exposure to pathogen- and damage-associated 
molecular patterns (PAMPS and DAMPs), at which point they drastically increase 
expression of chemokines, cytokines, leukotrienes and prostaglandins; these molecules 
orchestrate the host immune response and recruit other immune cells to the area9. Far 
from being relevant only during infection and damage, macrophages also reside under 
normal circumstances in the tissues where they have been found to be indispensable in 
maintaining homeostasis of the brain, bone, liver, gut, connective tissue, lung, lymph 
nodes, and spleen10.  
Macrophages were mainly thought to be derived from circulating blood 
monocytes that migrate into the tissues11 where they differentiate via exposure to 
macrophage-colony stimulating factor (M-CSF). More recently, however, it has been 
reported that some  resident tissue macrophages are derived from tissue-resident stem 





derived macrophages are triggered to migrate into tissue during infection and damage13, 
at which point they can remain in the tissues for the remainder of their lifespan as tissue-
resident macrophages.  
 
1.2 Macrophage Functions  
Macrophages have diverse roles in the body, including clearance of debris, 
recognition and destruction of pathogens, iron recycling, bone resorption, iron storage, 
cytokine production, immune regulation, wound healing, antigen presentation, 
ingestion of neutrophils, ingestion of cholesterol, muscle regeneration after exercise14, 
angiogenesis, thermoregulation15, and neuronal trimming16. The versatility of 
macrophages is made possible by its tissue heterogeneity; specifically, the 
specialization of the macrophage is determined by exposure to tissue-specific 
molecules during the macrophage’s differentiation. This effect is mediated through the 
activation of a tissue-specific enhancer regions, which preferentially promote 
transcription of certain genes dependent on exposure to factors in the extracellular 
milieu. The tissue-specific mediators also trigger the expression of transcription factors 
that function together with the lineage-determining transcription factor PU.1 to 
establish these enhancer regions17, setting the stage for the macrophages’ genetic 
responses throughout its lifespan. 
1.2.1 Phagocytosis  
The ability to engulf and digest pathogens and particles is a function of great 
practical importance18. The macrophage is especially equipped for this task, as its 





large objects. It is known as a “professional phagocyte”, due to its expression of FcRs 
and complement receptors19,20. These receptors allow macrophages to recognize and 
respond appropriately to its target. Furthermore, its arsenal of digestive enzymes, free 
radicals and other chemicals serves to give it superior digestive capabilities. For this 
reason, macrophages are considered important not only for janitorial purposes, but also 
as pathogen killers.  
1.2.2 Cytokines and chemokines 
Macrophages are a potent and important producer of cytokines and chemokines. 
These small and relatively unstable proteins are important mediators for intracellular 
communication, not only among immune cells, but also between immune cells and 
tissue cells. Ligation of TLRs or other pattern recognition receptors (PRRs) activates 
several cytosolic signaling molecules such as NFκB, ERK, p38, and interferon 
regulatory factors (IRFs), covered in more detail in subsequent sections. These 
molecules lead to upregulation in gene expression of potent inflammatory molecules 
such as TNFα, IL-1 IL-6, IL-12, and an array of chemokines such as CXCR6, which 
serve to recruit other immune cells to the area. The type, total amount, and proportions 
of these proteins that macrophages secrete can profoundly influence the behaviors of 
surrounding cells. This flexibility and plasticity allows the macrophage to orchestrate 
a sophisticated response appropriate to the pathogen or damage at hand.  
Macrophages are also an important source of IL-10, a cytokine with broad 
immunosuppressive activity that plays a pivotal role in the suppression of 
inflammation21,22. Knockout mice lacking this important immune regulator have a 





sepsis24, colon carcinoma23, and parasitic infections25. IL-10 knockout mice also 
develop spontaneous enterocolitis26, the mechanism for which appears to be dependent 
on the production of IL-127, a proinflammatory cytokine that is powerfully inhibited by 
IL-1028. More than a dozen transcriptional regulators have been confirmed as 
redundantly involved in IL-10 transcription, with NFκB, STAT3, Sp1, and CREB 
being among the best characterized thus far29.  
1.2.3 Matrix metalloproteinases 
Activated monocytes and macrophages are considered among the most 
important producers of matrix metalloproteinases, enzymes involved in tissue 
remodeling and angiogenesis. Matrix metalloproteinases (MMPs) were first discovered 
in 1962 in cultured tadpole tissue30. These proteases are secreted by endothelial cells, 
epithelial cells, and immune cells, and although they are not expressed under normal 
physiological conditions, they are collectively indispensable for tissue remodeling and 
angiogenesis31. Different types of MMPs are capable of degrading various types of 
extracellular matrix components such as collagen, elastin, and fibronectin, but have 
also been found to degrade and thus inactivate bioactive molecules including 
cytokines32–35. Monocytes and macrophages can produce high levels of various types 
of MMPs in inflammatory or other activating conditions, which contributes to tissue 
remodeling and angiogenesis necessary for tissue repair following infection36,37. The 
immunological activity of MMPs is still being studied, but knockout studies suggest 
that MMPs play a complex role that is both inflammatory and anti-inflammatory. For 
example, upon initial exposure to inflammatory stimuli, macrophages secrete MMPs, 





MMPs will later cleave chemokines, not only rendering them inactive but also able to 
act as chemokine receptor antagonists34. The diverse role of MMPs in both 
inflammation and healing makes them an exciting topic of research. 
1.3 Macrophage polarization  
1.3.1 Classical Activation 
A “classically activated” macrophage is defined as one that has been primed 
with INFγ and stimulated with lipopolysaccharide, initially defined by their ability to 
kill intracellular pathogens. These cells undergo a drastic change in protein expression 
characterized by inflammatory cytokine secretion, cellular adhesion, and production of 
reactive oxygen species that destroy phagocytized pathogens39. Lipopolysaccharide 
(LPS) is a molecule found on the outer membrane of gram-negative bacteria and ligates 
TLR4 (along with CD14, LPS binding protein), initiating MYD88- and TRIF- 
dependent signaling cascades that eventually leads to the activation of transcription 
factors such as NFκB40–42. NFκB and other activated transcription factors trigger 
production of inflammatory cytokines such as TNFα and interleukin 1 (IL-1)43, leading 
to generalized inflammatory activity. Simultaneously, LPS that leaks into the cytosol 
from vacuoles can directly bind caspase 11, triggering the assembly of the 
inflammasome complex necessary for activation of IL-144. The priming of the 
macrophage with IFNγ greatly increases the strength and duration of the cytokine 
response to LPS43; furthermore, it leads to the induction of IRFs through the activation 
of the STAT1 transcription factor45, which are important for the immune response 





suppressing activity of the mTORC pathway, which is thought to be involved in the 
limiting of inflammatory responses after TLR ligation47. This mechanism could explain 
the ability for IFNγ priming to amplify the inflammatory response.  
1.3.2 M1/M2 paradigm 
In the 1990’s the work of Siamon Gordon found that an “alternative” activation 
state of macrophages could be induced through  stimulation with IL-448. Treatment of 
macrophages with IL-4 upregulates mannose receptors and increases arginase 
production49, with little to no production of nitric oxide or inflammatory molecules. 
These macrophages have been found to be highly important in host defense against 
helminthic parasites50, homeostasis of adipose tissue51, and in the later stages of wound 
healing52. These studies helped develop the paradigm of bimodal macrophage 
activation, wherein activated macrophages are thought to be polarized along a 
continuum, ranging from inflammatory (M1) to anti-inflammatory (M2).  Classically 
activated macrophages, as well as those stimulated with PAMPs, DAMPs, and 
inflammatory cytokines, are all classified as M1, whereas all other activation states are 
classified as M2. Unfortunately, this model is an oversimplification. Although the 
introduction of this classification system contributed a great deal to the understanding 
of macrophage plasticity, enthusiastic attempts to fit all observations into this bipolar 
model have been problematic. Macrophages with any anti-inflammatory features have 
been incorrectly classified as subsets of M2, despite being  physiologically quite 
distinct, and in some cases more closely resembling M1 macrophage activation39,53. It 





activation39, in which a wide range of macrophage activation states exist (Illustration 
1), covered in more detail in the following section.  
1.3.3 Regulatory macrophages  
A third activation state, known as regulatory macrophage (R-Mϕ) activation, 
has been identified and characterized53. These macrophages are stimulated with a TLR 
ligand (typically LPS) along with a second “reprogramming” signal that modulates the 
actions of the TLR ligand, leading to an anti-inflammatory phenotype. Several of these 
reprogramming signals have been characterized, including, but not limited to, immune 
complexes, prostaglandin E2, adenosine, and apoptotic cells. An effective 
reprogramming signal suppresses the inflammatory cytokine response induced by LPS, 
while upregulating anti-inflammatory and immunoregulatory proteins such as IL-10. 
The discovery of this macrophage phenotype led to an updated model of macrophage 
activation that is represented by a color wheel39. The blending of the primary colors to 
produce the entire color spectrum is meant to indicate that an infinite number of 
activation states are possible, with the three primary colors being the polarized 
extremes. An imbalance in these activation states may lead to excessive or chronic 
inflammation in the case of classically activated macrophages, whereas excessive 








Illustration 1. Color wheel model of macrophage activation. (A) M1/M2 model of macrophage 
activation first proposed in the 1990’s. (B) An updated model represented by a color wheel that 
includes regulatory macrophages as a distinct phenotype, with the many intermediate phenotypes 
designated by the secondary colors. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Immunology, “Exploring the full spectrum of macrophage activation”, David M. Mosser 






The study of regulatory macrophage activation first began when Mosser and 
colleagues observed that macrophages treated with opsonized bacteria produced less 
IL-12 than macrophages infected with non-opsonized bacteria54. Later, it was found 
that the same response could also be induced by antibody-coated sheep’s red blood 
cells55, and immune complexes56, both of which induce Fcγ receptor cross-linking. 
These dual signals synergize to induce increased production of IL-10 and the EGF 
receptor ligand HB-EGF57, even when cells were primed with IFNγ. The IL-10 
response was found to be dependent on Fcγ chain signaling54 and could not induced by 
treatment with immune complexes alone. In the M1/M2 model of macrophage 
activation, this activation state has been (incorrectly) designated “M2b”, despite being 
genetically more similar to M1 macrophages53. Whereas M2a macrophage activation 
is known to involve STAT6 signaling, this is not the case with M2b macrophages. 
Rather, a transient ERK hyper-phosphorylation increases IL-10 transcription through 
transient chromatin remodeling at the IL-10 promoter58. Because of the decrease in 
inflammatory cytokines and increase in IL-10 and growth factors with this treatment, 
it is hypothesized that these cells play an important role in the tissue repair and the 
dampening of inflammation associated with the resolution of infection. Indeed, 
injection of mice with R-M-IC can rescue mice from lethal endotoxemia53. Almost all 
research studies on R-M-IC thus far have been carried out in mice.  No comprehensive 






1.3.4 Transcriptomic analysis of polarized macrophages 
Since the widespread availability of next-generation sequencing has enabled 
whole-transcriptome analysis of cell populations, there has been an overwhelming 
surge in information on macrophage polarization in both mouse and human cells. 
Previously, microarray techniques were frequently utilized to catalog global transcript 
changes, and this technique facilitated the relative quantification of thousands of genes. 
However, this method has several disadvantages: (1) because probes had to be designed 
for each transcript, the method restricts analysis to the number of probes that have been 
designed, in contrast to RNA-seq which can provide information on every gene 
expressed in the sample. (2) Microarray is unable to provide a comprehensive profile 
of transcript variants and unknown genes. (3) Microarray is unable to provide 
information about total transcript abundance, and (4) has limited sensitivity due to high 
background, reducing its ability to quantify low-abundance transcripts. As massive 
parallel sequencing technology became more accessible to researchers, there came to 
be a great increase in the amount of data that could be gleaned from one experiment. 
Currently, the entire transcriptome of a cell population can be characterized from only 
a small sample of RNA, providing a snapshot of the transcriptional activity of the cell. 
Although changes in RNA don’t necessarily lead to equal changes at the protein level59, 
through this analysis we can predict not only the way in which these changes could 
have physiological effects, but also which signaling pathways could give rise to these 
changes in gene expression. In the context of macrophage activation, high throughput 
studies have slowly led to the understanding that macrophages are highly sophisticated 





programs dependent on the exact environment to which they are exposed. In 2014, this 
diversity in gene expression was thoroughly profiled using RNA sequencing analysis 
on all known macrophage activation states in human cells60; the authors found that 
when looking at global changes in gene expression, macrophage activation states do 
not fall neatly along the M1/M2 bimodal continuum, but rather, selectively modify their 
gene expression upon exposure to different stimuli. This study illustrated that the 
complexity of macrophage activation states is best appreciated by looking at both 
global and functional analyses.  
1.4 Toll-like receptor signaling 
1.4.1 Toll-Like Receptors 
Cells of the innate immune system express an array of receptors known as 
pattern recognition receptors (PRRs). These receptors bind pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), 
which activate an inflammatory immune response61. PRRs are present both in the 
plasma membrane, facing either the extracellular environment or the internal side of 
endosomes, and are also present in the cytosol. One subset of the membrane bound 
PRRs is the toll-like receptor (TLR). TLRs are named after the drosophila homolog 
“toll”, which was discovered by Christiane Nüsslein-Volhard62, and further 
characterized by Bruno Lemaitre in 1996 when it was found to be necessary for host 
defense63. It was soon found that the requirement for innate immunity to trigger a robust 
adaptive immune response is explained largely by the action of toll-like receptors, 





activation. This discovery led to a revolution in the understanding of innate immunity 
and its interaction with the adaptive immune system5.  
There are eleven TLRs in humans, numbered accordingly, which have a 
leucine-rich repeat in their extracellular portion capable of binding molecules 
associated with pathogens64. PAMPs associated with viral infection, such as dsRNA 
and unmethylated DNA, bind to receptors TLR-365, TLR-7/866, and TLR-967. These 
receptors signal through TRAF3 leading to the activation of interferon regulatory 
factors68, transcription factors that are important for driving the cell-mediated immune 
response most appropriate for intracellular cytosolic pathogens. TLRs that bind to 
components of bacteria, such as flagellin (TLR-5), peptidoglycan (TLR-1/2), bacterial 
lipopeptides (TLR-2/6) or lipopolysaccharide (TLR-4), initiate a broad inflammatory 
response appropriate for host defense against extracellular pathogens; this includes the 
production of antibody to increase efficiency of phagocytosis and accelerated killing 
of gram-negative bacteria through complement fixation. The ability for the immune 
system to tailor its immune response toward a particular pathogen originates in the 
PRR-specific genetic responses observed in antigen-presenting cells upon first 
encountering a pathogen. This flexibility and specificity in response allows the host to 
minimize collateral damage while maximizing host defense. 
1.4.2 TLR signaling pathways 
TLR ligation leads to activation of several signaling cascades, broadly 
classified into MYD88- and TRIF-dependent pathways69. Ligation leads to 
conformational changes in the intracellular portion of the receptor, allowing the adaptor 





TRAF6. All of the TLRs signal through MYD88 with the exception of TLR3, which 
signals only through TRIF61. MYD88 activation primarily leads to activation of NFκB 
and the MAPK cascade, both heavily involved in the transcriptional control of 
cytokines, chemokines, and immunoreceptors. The MAP kinases include ERK, p38, 
and JNK, all of which activate Sp1 and the AP-1 family of transcription factors, 
contributing to transcription of genes related to inflammation and cell survival. TRIF 
is another TLR-associated adaptor molecule that is activated by both TLR3 and TLR4 
ligation. Less is known about the downstream signaling of TRIF, but it was found to 
be essential for the IRF3 activation necessary for IFNβ transcription70, and is also able 
to activate NFκB through cleavage of caspases 8 and 1071.  
Besides transcriptional changes, activated macrophages undergo profound 
alterations in metabolism, translation efficiency, and post-translational modification of 
intracellular signaling proteins. These changes coincide with several mechanisms of 
negative regulation that exert control over the cellular response and allow the cell to 
return to a resting state. For example, activation of Akt, TBK1, and IKKε by TLR 
ligation leads to increased activity of the glycolytic pathway72. This in turn increases 
intracellular ATP, which is released into the extracellular environment in small 
amounts. This released ATP is then converted by ectonucleotidases into adenosine, 
which activates adenosine receptors, thus suppressing the cytokine response73. Other 
mechanisms of feedback inhibition include the LPS-induced production of decoy 
receptors such as sTLR4 and sTLR2, release of PGE2, inhibitory microRNAs that 
target pro-inflammatory transcripts for degradation, phosphatases that remove 





ligases that target TLR signaling mediators for proteasomal degradation74. This broad 
collection of self-limiting mechanisms at all levels of regulation emphasizes the 
importance of autoregulation in the inflammatory response, and the potential harm that 
inevitably stems from unchecked inflammation. 
 
1.4.3 NFκB 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a 
well-characterized transcription factor responsible for driving a cellular response to 
TLR ligands41 and any receptor which acts through the adaptor molecule MyD8875. It 
can also be activated by oxidative stress, cytokine signaling, and DNA damage76. It has 
a profound effect on many genes, particularly cytokines, and can be activated in less 
than half an hour after the cell has encountered a triggering stimulus77. There are five 
NFκB proteins separated into two classes. In class I are p50 (NF-KB1) and p52 (NF-
KB2) which both contain ankyrin repeats in their C-termini which have transrepression 
activity. Class II members include RelA (p65), RelB, and c-Rel, differentiated from 
those in class I by the presence of a transactivation domain in their C-termini. In the 
canonical model of transcriptional activation, NFκB forms a heterodimer composed of 
p50 and p6578 which, under resting conditions, is prevented entry into the nucleus by 
its binding to nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor alpha (IκBα)79. Upon activation of TLR ligands or cytokine receptors, IκBα 
is degraded by IκB kinase, allowing NFκB to enter the nucleus and control gene 
transcription. The various subunits can associate in different ways to perform distinct 





form a homodimer which drives transcription of the anti-inflammatory cytokine IL-
1080. Thus, while NFκB is highly important for cytokine response in macrophages, it 
is involved in transcription of both inflammatory and anti-inflammatory genes81. Thus, 
efforts to develop anti-inflammatory therapies by targeting NFκB may have 
unpredictable effects81.  
1.4.4 Akt 
More recently it was discovered that the Akt/mTOR pathway plays a complex 
but highly important role in the regulation of the cytokine response. Akt (also known 
as protein kinase B) is a 60 kDa serine threonine protein kinase that acts as a sensor for 
the health and nutritional status of the cell, as well as a central regulator in the growth 
factor signaling cascade. It is known to phosphorylate dozens of substrates and lies 
upstream of several important cellular processes including gene regulation, cell growth 
and proliferation, utilization of nutrients, regulation of metabolism, and cell survival 
(Illustration 2). One of its most well-known activators is PI3K, which directly activates 
Akt through phosphorylation, and which itself is known to be activated by Fc receptor 
activation82. Akt is then able to phosphorylate dozens of substrates, and indirectly leads 
to activation of mammalian target of rapamycin (mTOR) through inhibition of TSC1. 
mTOR is itself a central modulator of metabolic signaling, including the well-known 
increase in glycolytic flux observed after activation of macrophages. This increase in 
glycolysis allows a rapid albeit inefficient production of high levels of ATP necessary 








Illustration 2. Overview of Akt pathway. Illustration courtesy of Cell Signaling Technologies 






LPS has been observed to activate Akt and downstream pathways through 
activation of PI3K, but the degree and effects of this activation appear to be context-
specific. Akt1 is the isoform that can be activated by TLR ligation, which has been 
found to be necessary for the production of anti-inflammatory microRNAs such as let-
7e83. Systemically, Akt appears to plays a role in negative regulation of inflammation, 
as Akt1-specific knockout mice are more susceptible to lethal endotoxemia and have 
higher levels of several inflammatory cytokines84. However, because Akt is so readily 
effected by nutritional status of the cell and exposure to growth factors present in 
serum, the effect of TLR ligation on phosphorylation of Akt varies considerably. 
1.4.5 ERK  
Also known as the Ras-Raf-MEK-ERK signaling pathway, the MAPK cascade 
is an important and prominent chain of cytosolic signaling events involved in 
extracellular signal transduction and leads to widespread effects on transcriptional 
regulation. It is one of the most well-characterized downstream mediators of growth 
factor signaling, and is highly upregulated in active tumors85. In murine macrophages, 
the MAPK/ERK pathway is involved in proliferation triggered by FcR mediated 
phagocytosis86, and acts to upregulate IL-10 through chromatin modification at the IL-
10 promoter58. Although LPS alone can increase in ERK activation in macrophages, 
cross-linking of Fc receptors by immune complexes leads to hyperphosphorylation of 
ERK within the first half hour following stimulation. ERK phosphorylates a myriad of 





transcription. In macrophages, it is involved in the regulation of both inflammatory and 
anti-inflammatory cytokines through its activation of the transcription factor AP-1.   
1.5 Other signaling pathways in activated macrophages 
1.5.1 FC receptors 
Fc receptors are a class of cell-surface receptors belonging to the 
immunoglobulin gene family and recognize the Fc portion of antibodies. These 
receptors are expressed on the surface of hematopoietic cells, and trigger physiological 
functions specific to the cell type. There are several classes of FcR, designated with a 
greek symbol corresponding to the antibody isotype that they recognize. The Fcγ 
receptor is specific for IgG antibody, and in humans is found in three isoforms: FcγRI 
(CD64), FcγRII (CD32), and FcγRIII (CD16). FcγRI and FcγRIII associate with the 
common γ-chain, encoded by FCER1G, which contains an immunoreceptor tyrosine-
based activation motif (ITAM) in the intracellular region87. FcγRIIA does not 
associated with the common gamma chain, but signals through an ITAM contained in 
the intracellular portion of the receptor. FCγRIIB is similar to FcγRIIA in structure, 
except that it contains an ITIM motif which leads to inhibitory signaling (Illustration 
3).  
Exposure of the FcRs to immune complexes or opsonized particles leads to 
aggregation of the FcR ITAMs, which enables them to be phosphorylated by Src family 
kinases88. The phosphorylation of these ITAMs is necessary for the recruitment and 
subsequent phosphorylation of spleen tyrosine kinase (Syk)89, a molecule necessary for 







Illustration 3. Properties of Fcγ receptors in mouse and human. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Immunology, “Fcγ receptors as regulators of immune 





macrophages. Because of the nature of its activating mechanism, Fc receptor ligation 
in the absence of cross-linking does not induce the same signaling cascades55, 
preventing cellular activation by antibody in the absence of bound antigen.  
The physiological effect of Fc receptor ligation is context specific, and is often 
associated with increased inflammation by neutrophils93,94 and NK cells95. In 
macrophages, cross-linking of Fc receptors by opsonized pathogens potentiates a 
powerful signaling cascade initiated by the phosphorylation of Syk89, leading to 
activation of the MAPK pathway, actin remodeling, and Ca+ mobilization96, all 
enabling the macrophage to phagocytose the opsonized particles. Kinetics studies of 
macrophages treated with immune complex confirmed that the clustering of many Fc 
receptors gives rise to recruitment and subsequent phosphorylation of Syk97. The 
molecular mechanisms involved in the induction of phagocytosis are complex, and 
require phosphorylation of PI3K and activation of the MAPK pathway through Ras and 
Raf. Phosphorylation of PI3K leads to BTK and PLCγ activation, subsequently 
increasing cytosolic calcium levels98. Although Syk is critical for FcγR-mediated 
phagocytosis by macrophages99, inhibition of Syk is also associated with upregulation 
of inflammatory cytokine production in macrophages100.  
1.5.2 GSK3 
Glycogen synthase kinase 3 is an unusual signaling protein that typically 
inactivates its substrate upon phosphorylation rather than activating it. Furthermore, 
unlike most other signaling molecules this kinase is inactivated when it is itself 
phosphorylated because the phosphate group physically blocks substrate binding101. 





mainly a regulator of glycogen synthesis. Since then, over 100 substrates for this 
molecule have been proposed, most of which are transcription factors103. Research into 
GSK3 increased dramatically after it was found to be relevant in neurobiology, as it is 
thought to be responsible for the effects of lithium on bipolar disorder. More recently 
GSK3 has also been found to be important in the regulation of inflammation104, with 
GSK3 inhibition associated with a down-regulation of inflammatory responses. 
Specifically, it was found that Akt activation is able to induce activation of AP-1 and 
CREB through inactivation of GSK3, which normally has a suppressive effect on these 
transcription factors 105. This release of AP-1 and CREB leads to an increase in IL-10 
transcription, explaining one mechanism by which Akt activation can contribute to IL-
10 production in human macrophages. This observation was replicated in a study 
examining the effect of Leishmania infection on IL-10, where they found that Akt2 led 
to phosphorylation of GSK3 at serine 9. The resulting inhibition of GSK3 nuclear 
translocation allowed CREB to promote IL-10 transcription106. GSK3 inhibition has 
also been found to be involved in angiogenesis107,108, but the mechanism for this is still 
unknown. 
1.6 Sepsis 
1.6.1 Incidence and Cost 
Sepsis is one of the most widespread and costly conditions treated in hospitals 
in the United States. In fact, deaths from sepsis outnumber mortality due to both breast 
and prostate cancer combined109. Sepsis is ranked the top most expensive condition in 





rises every year by about 12%110. Furthermore, incidence of sepsis deaths has increased 
in recent years, and is expected to increase as the population ages.  
1.6.2 Etiology 
Risk of sepsis is associated with old age, as well as lifestyle factors such as 
smoking and alcohol use. It is also strongly associated, likely causally, with chronic 
diseases such as heart disease, diabetes, stroke, and hypertension. Immunosuppressed 
individuals such as those being treated with chemotherapy for cancer, can develop 
infection leading to sepsis. Other risk factors include long-term catheter use, surgical 
procedures, recreational drug use, burns, long-term steroid use, and pregnancy. The 
majority of infections leading to sepsis begin in the lungs, so any condition or injury 
that leads to pneumonia also increases risk of sepsis111.  
1.6.3 Physiology 
Although death is ultimately caused by the patient’s immune response112, poor 
immunity is a risk factor for the development of sepsis because a sensitive and 
responsive immune system is able to prevent widespread infection upon initial 
exposure to the pathogen113. Upon widespread dissemination of the pathogen, the host’s 
production of TNF and IL-1 is often (but not always) the ultimate cause of multiple 
organ failure and death, which is likely why anti-TNF therapies have been effective in 
reducing sepsis mortality if administered early114. In recent years, gram-positive 
bacteria account for 50% of sepsis cases, but sepsis can also be caused by viruses and 





The role of macrophages in the pathophysiology of sepsis is multi-faceted. On 
the one hand, a poor initial immune response or excessive tolerization to endotoxin 
leaves the patient vulnerable to the infectious agent. On the other hand, the 
inflammatory cytokines that ultimately lead to vascular leakage and multiple organ 
failure are produced mainly by macrophages; a hyperactive immune response in this 
respect can increases risk of mortality before antibiotic treatment has the opportunity 
to clear the infection. In human patients, the presence of M1 markers of macrophage 
activation such as IL-1β and IL-6 predicts imminent mortality116. In baboons, mortality 
was correlated with M1 markers secreted from monocyte isolated during infection, 
whereas a mixed M1/M2 phenotype predicted resistance to bacterial sepsis117. For this 
reason, the macrophage response is considered crucial in the understanding of 
immunological management of the disease. 
1.6.4 Current Treatments 
Sepsis is an extremely dangerous condition that requires intensive hospital care. 
Constant monitoring is necessary to detect and respond to potentially fatal changes in 
blood pressure, respiration and heart rate. In the case of bacterial septicemia, 
appropriate antibiotics, usually of multiple types, are administered intravenously. In the 
case of a hyperinflammation, low doses of corticosteroids are used to dampen the 
cytokine response. IV fluids and vasopressors are used to prevent a lethal drop in blood 
pressure118. Given the 38% mortality rate despite these measures119, the need for more 






In a descriptive study of several M2 macrophage polarization states, Fleming et 
al. revealed that IC has a potent anti-inflammatory phenotype in murine macrophages, 
and that this phenotype is similarly observed in primary human macrophages. In this 
study, we intend to thoroughly examine this activation state in human monocyte-
derived macrophages (HMDMs) in order to explore its molecular regulation and 
functional significance. The effect and control of the R-Mϕ-IC phenotype is yet to be 
thoroughly characterized in human macrophages, and no biomarkers exist to identify 
this activation state in human tissue. Here we intend to use a multi-omics approach to 
characterize M2b macrophages and identify key regulators of gene expression. We 
have examined the transcriptome and secretome of regulatory macrophages, which has 
provided us with a global picture of the behavior and function of these cells. We 
propose that these studies could be applicable to a wide range of disease states where 





Chapter 2: Materials and Methods 
2.1 Differentiation of human monocyte-derived macrophages 
Human monocyte-derived macrophages (HMDMs) were either purchased from 
HemaCare Corporation (Van Nuys, CA) or differentiated in house. PBMCs were 
obtained from 50 milliliters of human blood by Ficoll-paque density gradient 
centrifugation. Pure unlabeled monocytes were isolated from PBMCs using the pan 
monocyte isolation kit from Miltenyi Biotec (San Diego, CA) and cultured for 7-10 
days in X-VIVOTM 15 serum-free media (Lonza, Walkersville, MD) containing 1% 
penicillin-streptomycin, 1% L-glutamate (Gibco, Gaithersburg, MD), and 30 ng/mL 
recombinant human M-CSF (Peprotech, Rocky Hill, NJ). The night before stimulation, 
M-CSF-containing media was removed and replaced with X-VIVOTM 15 media 
containing 2.5% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA). For 
some experiments (noted in figure legends) macrophages were purchased from 
HemaCare, (product PBM2-MON; M-CSF-differentiated) and plated upon arrival in 
X-VIVOTM15 medium with 2.5% FBS and stimulated the following day. All studies 
on human monocyte-derived macrophages were approved by the University of 
Maryland, Institutional Review Board. A signed informed consent was obtained from 
each healthy volunteer who donated blood.  
2.2 Cell culture and stimulation 
LPS-stimulated macrophages (LPS-M) were generated by adding 30 ng/ml 
Ultra-pure LPS from Escherichia coli K12 (Invivogen, San Diego, CA). Regulatory 





ng/ml LPS and 80 µl OVA-IC per million macrophages (designated as LPS+IC in text). 
Immune complexes were prepared by combining 1 mg/ml ovalbumin (Worthington, 
Lakewood, NJ) with 10 mg/ml anti-ovalbumin (Polysciences, Warrington, PA) at a 
1:20 v/v ratio and incubating at room temperature for 30 minutes before use.  
2.3 RNA-sequencing sample preparation 
After 4 hours of stimulation, media was removed and the RNA was extracted 
from the cells using the mirVANA kit by Ambion (ThermoFisher Scientific, Waltham, 
MA) according to the manufacturer’s protocol. PolyA-enriched cDNA libraries were 
generated using the Illumina TruSeq RNA sample prep kit (Illumina, SanDiego, CA). 
2.4 RNA-seq data generation, pre-processing, and quality trimming 
Paired end reads (100 bp) were obtained from the Illumina HiSeq 1500 platform 
(Illumina, SanDiego, CA). Trimmomatic was used to remove any remaining Illumina 
adapter sequences from reads and to cut off bases with quality score less than 20 120. 
Sequence quality metrics were assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Mapping cDNA 
fragments to the reference genome, abundance estimation, and data normalization. 
Reads were aligned to the human genome (hg19/GRCh37.62.v3) obtained from the 
UCSC genome browser121 (http://genome.ucsc.edu) using TopHat (v 2.0.13)122. Two 
mismatches per read were allowed and reads were allowed to map only to a single 







2.5 RNA-sequencing data quality assessment by statistical sample clustering and 
visualization 
Multiple approaches were used to evaluate replicates and to visualize sample-
sample distances. Those included Pearson correlation, Box Plots, Principal Component 
Analysis (PCA) and Euclidean distances-based hierarchical clustering. All components 
of the statistical pipeline, named cbcbSEQ, can be accessed on GitHub 
(https://github.com/kokrah/cbcbSEQ/). 
2.6 RNA-sequencing differential expression analysis 
Non-expressed and weakly expressed genes, defined as having less than 1 read 
per million in n of the samples, where n is the size of the smallest group of replicates123 
(here n=3), were removed prior to differential expression analysis. A quartile 
normalization scheme was applied to all samples124. Following log2 transformation of 
the data, Limma (a Bioconductor package) was used to conduct differential expression 
analyses. Limma utilizes a standard variance moderated across all genes using a 
Bayesian model and produces p values with greater degrees of freedom125. The voom 
module was used to transform the data based on observational level weights derived 
from the mean-variance relationship prior to statistical modeling. Experimental batch 
effects were adjusted by including experimental batch as a covariate in our statistical 
model. Differentially expressed genes were defined as genes with a Benjamini-







RNAscope probes for Interleukin 10 (IL-10), leukemia inhibitory factor (LIF), 
and matrix metalloproteinase 10 (MMP10) were custom designed by Advanced Cell 
Diagnostics (Newark, CA), accession numbers: NM_000572 (IL10), NM_002421 
(MMP1), NM_002309 (LIF). HMDMs were cultured and stimulated in 4-well chamber 
slides for 4 hours. Supernatants were removed, cells were washed and then fixed for 30 
minutes in 4% paraformaldehyde, dehydrated and stored in 100% ethanol. Slides were 
then rehydrated and staining was done according to manufacturer’s protocol 
(RNAscope Multiplex Fluorescent Reagent Kit v2 User Manual, 
http://www.acdbio.com/support/technical-doc). After staining, slides were mounted 
with Fluoromount-G™ with DAPI (ThermoFisher Scientific, Waltham, MA). Slides 
were imaged using the Zeiss LSM710 confocal Laser microscope (Carl Zeiss 
Microscopy GmbH, Jena, Germany) and fluorescence was quantified using Zen 
software by Zeiss.  
2.8 Flow cytometry 
Human monocytes were cultured and stimulated in ultra-low attachment plates 
for a week to obtain macrophages for flow cytometry.  Staining for surface or 
intracellular protein expression was performed following standard protocols 
recommended by the antibody manufacturer. FITC conjugated CD274, CD68; PE- 
conjugated CD93, CXCR4, CD66b, TM4SF1, MMP-1, IL-6, IP-10 and APC 
conjugated DC-STAMP, CD49b, LIF, NOTCH-2 antibodies were used for flow 
cytometry. The antibodies for NOTCH-2 and DC-STAMP (cat # FAB7824A) were 





eBioscience (San Diego, CA); and IP-10, CD49b from Biolegend (San Diego, CA). All 
other antibodies were purchased from BD Biosciences (Franklin Lakes, NJ). Data 
acquisition was carried out in FACSCanto II (BDbiosciences, Franklin Lakes, NJ 
USA), and analyses were done on FlowJo version 10. 
2.9 SOMAscan™ assay 
Cell culture supernatants were collected from human macrophages 24 hours 
after stimulation (NS, LPS, and LPS+IC), flash frozen at -80 C, and were analyzed 
using the SOMAscan™ proteomic assay (SOMAscan Assay 1.1k; SomaLogic; 
Boulder, CO). SOMAscan is a protein biomarker discovery platform that utilizes 
SOMAmers (Slow Off-rate Modified Aptamers), single-stranded DNA aptamers with 
modified nucleotides, that bind to specific proteins in the sample and are subsequently 
quantified. SOMAmers were mixed with samples to allow binding; sample 
concentrations of 40%, 1%, and 0.005% were used to allow measurement of protein 
concentrations at ~8 log range. Unbound SOMAmers were then washed away. Protein-
bound SOMAmers were eluted and quantified using a DNA microarray. In this way, 
protein concentrations in the supernatant were transformed into a corresponding 
signature of DNA aptamer concentrations followed by a fluorescence signal on the 
DNA microarray. Values are reported in relative fluorescence units (RFU). The 
SOMAscan assay quantified relative levels of 1,129 proteins in each sample. For some 
analyses, intracellular proteins were excluded from the analysis to leave only secretory 
proteins (subcellular localization information was gathered from GeneCard). 
Prior to analysis, RFU values from SOMAscan™ assays were normalized 





during hybridization. Median normalization was performed across samples within an 
array. Finally, calibration was performed based on calibrator samples in each array to 
allow comparison of samples across runs. To reduce heteroscedasticity, values were 
log2 transformed. Group comparisons were performed using Bayesian modified linear 
model using the Limma package in R126. Default parameters were used, except the 
“proportion” parameter was set to 0.05. Between groups, comparisons were assessed 
using contrast and the p-values of the moderated-t-test were adjusted by the Benjamini–
Hochberg procedure which controls the false discovery rate (FDR). Differentially 
expressed proteins were defined as those with fold change (FCH) ≥1.5 and FDR ≤0.05.  
2.10 ELISA 
Human IL-10 and IL-12p40 were detected by use of ELISA kits purchased from 
eBioscience (San Diego, CA, USA). ELISA kits for the remaining analytes were 
purchased from R&D (Minneapolis, MN). 
2.11 Cyclic AMP measurement 
A direct colorimetric cAMP ELISA kit was purchased from Enzo Life Sciences 
(Farmingdale, NY) and used according to manufacturer’s instructions to analyze 
HMDM cell lysates 2 minutes after stimulation.  
2.12 Bioinformatics Analyses 
Ingenuity Pathway Analysis (IPA) software127 was used to predict diseases and 
functions associated with LPS and LPS+IC stimulated macrophages, and to predict 





analysis included genes that showed at least a two-fold up-regulation or down-
regulation (p-value <0.05) when compared to macrophages stimulated with LPS alone.  
For the Upstream Regulators Analysis, the resulting predicted regulators list 
was limited to members of intracellular signaling pathway members by restricting them 
to those located in the cytosol (molecule types included: kinase, group, enzyme, 
complex, and other). Regulators with a low number of known targets were removed 
(cutoff = 10) to limit false positive findings.  
Gene Set Enrichment Analysis (http://www.broadinstitute.org/gsea/index.jsp) 
was performed using the GSEA software using log2 transformed RPKM values in LPS 
and LPS+IC, to assess overlap with datasets in the Molecular Signature Database 
(MSigDB). Specifically, data were compared to collections C2 and C3, containing 
curated gene sets and transcription factor targets respectively128,129. 
2.13 Antibody array 
The PathScan Akt Signaling Antibody Array Kit (Cell Signaling Technologies, 
Danvers, MA) was used to assess the relative differences of 16 phosphorylated 
signaling molecules within the Akt signaling pathway. Whole cell lysates were 
obtained 20 minutes after stimulation as described in ‘Cell culture and stimulation’ 
section, and a BCA assay (Pierce Biotechnology, Waltham, MA) was used to determine 
protein concentration of the samples. The array was performed according to the 





2.14 Western blotting 
Protein samples for western blotting were prepared by lysing the cells with 
radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase 
inhibitors (ThermoFisher Scientific, Waltham, MA). For blots in which nuclear and 
cytosolic fractions were isolated, the NE-PER nuclear extraction kit (ThermoFisher 
Scientific, Waltham, MA) was used with sonication prior to centrifugation of nuclear 
debris. Protein lysates were incubated for 2 hours at 4°C with protein agarose A (Santa 
Cruz Biotechnology, Inc., Dallas, Texas) to clear the lysate of any residual anti-
ovalbumin from macrophage stimulation. Antibodies for phospho-ERK 1/2, phospho-
Akt, cofilin, phospho-GSK3β, GSK3β, histone H3 were purchased from Cell Signaling 
Technologies (Danvers, MA); the antibody for phospho-GSK3α/β was purchased from 
R&D Systems (Minneapolis, MN); the actin antibody was purchased from Santa Cruz 
(Dallas, Texas). To reduce cross-reactivity of secondary antibody with anti-ovalbumin 
in the protein isolate, a conformation-specific anti-rabbit IgG (Cell Signaling 
Technologies, Danvers, MA) was used as the secondary antibody against those primary 
antibodies derived from rabbit. 
2.15 Luminex assay 
A magnetic bead Luminex kit with a custom set of analytes was purchased from 
R&D Technologies (Minneapolis, MN). The Luminex assay was run according to 
manufacturer’s instructions using supernatants from HMDMs that had been stimulated 
for 16 hours. Beads were quantified using a Luminex MagPixTM instrument (Austin, 





2.16 Quantitative Real-time PCR (qRT-PCR) 
RNA for qRT-PCR was isolated using the Trizol method (ThermoFisher 
Scientific, Waltham, MA). Complementary DNA was synthesized from 2 µg 
equivalent of RNA using Superscript® ViloTM cDNA synthesis kit (ThermoFisher 
Scientific, Waltham, MA). Relative quantification of RNA was done using SYBR-
Green based real time PCR (ThermoFisher Scientific, Waltham, MA). The samples 
were run in Roche Light Cycler® 480, in a 384 well plate, each well containing 10 ng 
of cDNA, 1.5 µl each of sense and anti-sense primers (5 pmol), 6 µl of nuclease free 
water and 10 μl of 2X Sybr-Green PCR master mix. For data analysis, the comparative 
threshold cycle (CT) value for beta actin was used to calculate relative differences. The 
fold induction of RNA was calculated using 2^(-ΔΔCT)131. Sequences used for primer 
pairs are listed in Table 1.  
2.17 Inhibitors 
The Akt inhibitor MK-2206 2HCl, GSK3 inhibitor sb415286, and ERK 
inhibitor U0126 were purchased from ApexBio (Houston, TX), Cayman Chemicals 
(Ann Arbor, MI) and Cell Signaling Technologies (Danvers, MA) and were used at 20-
, 20- and 10- µM concentrations, respectively.  
2.18 Endotoxemia 
Female C57bl/6 mice (between 9 and 11 weeks old) were injected with 2x105 
HMDMs that had been stimulated for 60 minutes with 30 ng/mL LPS, or LPS and 10 





Mice were checked every 12 hours for survival. In each independent experiment, one 
group of littermates was used which were co-housed. 
2.19 Statistics 
Non-parametric t tests were performed to calculate the significance of the 
observed differences. A p value of <0.05 was considered to be significant in all the 










Accession number Gene Sequence  
NM_000572.2 IL10 
 
 Forward primer 5’-ACGGCGCTGTCATCGATTT-3’ 
 Reverse primer 5’-CAGAGCCCCAGATCCGATTTT-3’ 
NM_001101.3 ACTB 
 
 Forward primer 5’-GCCGCCAGCTCACCAT-3’ 
 Reverse primer 5’-TCGATGGGGTACTTCAGGGT-3’ 
NM_002192.3 INHBA 
 
 Forward primer 5’-GGGGACCAGAAAGAGAATTTGC-3’ 
 Reverse primer 5’-CCTCTCAGCCAAAGCAAGGG-3’ 
NM_002422.4 MMP3 
 
 Forward primer 5’-GTCCCTCTATGGACCTCCCC-3’ 
 Reverse primer 5’-AGGGATTTGCGCCAAAAGTG-3’ 
NM_139314.2 ANGPTL4 
 
 Forward primer 5’-CTTGGGACCAGGATCACGAC-3’ 
 Reverse primer 5’-AAACCACCAGCCTCCAGAGAG-3’ 
NM_002426.5 MMP12 
 
 Forward primer 5’-GGCCCGTATGGAGGAAACAT-3’ 
 Reverse primer 5’-GGAAGTCTCCATGAGCTCCAC-3’ 
NM_000759.3 CSF3  
 
 Forward primer 5’-TGAGTGAGTGTGCCACCTACAA-3’ 
 Reverse primer 5’-TGGTAGAGGAAAAGGCCGCT-3’ 
NM_000602.4 SERPINE1 
 
 Forward primer 5’-GACCGCAACGTGGTTTTCTC-3’ 
 Reverse primer 5’-GCCATGCCCTTGTCATCAAT-3’ 
NM_002421.3 MMP1 
 
 Forward primer 5’-CCTGGAAAAATACTACAACCTGAAG-3’ 
 Reverse primer 5’-TTCAATCCTGTAGGTCAGATGTGT-3’ 
NM_004591.2 CCL20 
 
 Forward primer 5’-TCAGAAGCAGCAAGCAACTTT-3’ 
 Reverse primer 5’-GATTTGCGCACACAGACAACT-3’ 
NM_002425.2 MMP10 
 
 Forward primer 5’-GGATCTTGCCCAGCAATACCTA-3’ 





Chapter 3: Results 
3.1 Transcriptomic analysis of Human Macrophages with a Regulatory Phenotype 
In our previous studies we identified  a population of murine macrophages with 
an immuno- regulatory phenotype, capable of inhibiting inflammatory responses53. We 
named these cells regulatory macrophages (R-Mϕ).  We further demonstrated that R-
Ms were transcriptionally and functionally different from alternatively activated M2a 
macrophages and began to identify potential candidate biomarkers for mouse R-Ms. 
In the present study, we set out to study the transcriptome of human monocyte-derived 
macrophages with an immunoregulatory phenotype, and to characterize global changes 
in gene expression in these cells upon stimulation. RNA-sequencing analysis was 
performed on non-stimulated resting macrophages (NS-M), M1 macrophages 
stimulated with lipopolysaccharide (LPS-M), and R-Ms stimulated with LPS in the 
presence of immune complexes (R-M-IC). RNA samples were collected four hours 
after stimulation to capture the “first wave” of gene expression following stimulation.  
This early analysis avoids potential complications due to secondary effects, such as 
those associated with autocrine action of secreted cytokines. 
3.1.1 Basic analyses of RNA-sequencing results 
We first examined the variations in individual gene transcripts by plotting all 
log transformed reads per kilobase per million (RPKMs) that meet minimal expression 
criteria (arbitrary threshold cutoff <0.1 RPKMs averaged across all samples). RPKMs 
were calculated using the edgeR package in R and resulting values were plotted to 





samples from the same treatment group clustering together, and provided visual 
representation for LPS or LPS+IC-driven changes in gene expression (Figure 1A). 
Next, to determine total degree of variance among datasets, principal component 
analysis (PCA) was performed (Figure 1B). As shown in the PCA plot, samples 
grouped together according to treatment conditions, indicating minimal variance 
among donors. Principal component 1 explained 75% of the variance in global gene 
expression, separating resting cells from those stimulated with LPS. Principal 
component 2 segregated LPS-M from R-M-IC by a 13% variance (Figure 1B). These 
analyses indicate that the presence of LPS accounts for a greater amount of variance in 
global gene expression than does the addition of IC. 
3.1.2 Analysis of differentially expressed genes 
Next, differentially expressed genes (DEGs) were identified with the Limma 
package in R, using a fold change cutoff of 2 and a p-value of <0.05. Stimulation with 
LPS resulted in numerous changes in gene expression, as previously reported132,133. 
Over 4,500 genes were differentially expressed in response to LPS, accounting for 
approximately 38% of all detectable genes in the transcriptome as defined by a 
minimum of 1 count in each sample (Figure 2A). 
To compare gene changes among the conditions, a scatterplot was made to show 
all fold change values in LPS-M and R-M-IC, both compared to baseline levels in 
resting cells (Figure 3A). The positive correlation observed in the plot is assumed to be 
due to the presence of LPS in both groups. The divergence from this linear correlation 
indicates the effect of the IC; genes that are differentially regulated to a significant 






Figure 1. Basic analysis of RNA-sequencing results for LPS-M and R-M-IC. Human 
monocyte-derived macrophages purchased from HemaCare were stimulated with LPS (LPS) or LPS 
with immune complexes (LI) for 4 hours and total mRNA was isolated and sequenced on an Illumina 
platform. (A) Heatmap of RPKMs in each sample tested, threshold cutoff 0.1, uses 
Euclidean distance and complete agglomeration method for clustering. Numbers following sample 
name denote the donor from which the sample was obtained. (B) Principal component analysis to 
visualize variance among samples. Data for figures were generated with assistance from Stephen 





Figure 2. Differentially expressed genes. Pie graphs illustrating the DEGs in LPS-M vs NS-M 
(A), or R-M-IC vs LPS-M (B), as a percentage of total detectable genes in the transcriptome. The 







Figure 3. IC modulates the effect of LPS, suppressing genes involved in inflammation and host 
defense. (A) Gene changes for LPS (x axis) and LPS+IC (y axis) compared to resting cells. Data 
points for genes that are differentially regulated between LPS and LPS+IC are indicated in blue. (B) 
The top 10 most highly upregulated transcripts following LPS stimulation for 4 hours. Values for 





genes in LPS-M are presented in Figure 3B. Consistent with previous reports 132,134, 
LPS stimulation leads to increased production of inflammatory mediators such as the 
chemokines CXCL9, -10, and -11 and the cytokines IL-6 and IL-12B. Indolamine 
dioxygenase, an enzyme that limits tryptophan availability, was also highly expressed 
in human macrophages in response to LPS stimulation (Figure 3B, red). Treatment with 
LPS+IC resulted in an immune-regulatory phenotype in macrophages as observed by 
the downregulation of several of the LPS-induced inflammatory mediators (Figure 3B, 
blue).   
Analysis of LPS+IC-driven changes in gene expression showed 1,557 genes 
were differentially expressed compared to LPS-stimulation alone, equaling 13% of 
total detectable genes in the transcriptome (Figure 2B, Figure 4A). IC also differentially 
regulated many genes compared to resting cells that were not changed in LPS-M, 
numbering 1,497 genes in total (Figure 3A). Among the most significantly upregulated 
genes induced in R-M-IC (Figure 4A, magnified in the volcano subset box) were 
several proteins with known immunomodulatory and angiogenic functions, highlighted 
in red for emphasis. IL-10 appeared in this subset, which was previously observed to 
be upregulated in murine R-M-IC and found to have anti-inflammatory activity in 
mice53. Also highlighted is amphiregulin, a member of the EGF family of growth 
factors which can bind to EGFR to promote cell growth135. Figure 4B lists the top 10 
differentially upregulated and downregulated genes of R-M-IC compared to LPS-M. 
Among  the 10 most upregulated genes were the matrix metalloproteinases MMP1, 
MMP3, and MMP10, which are known to be involved in tissue remodeling, 








Figure 4. The addition of IC results in significant changes in global gene expression compared 
to LPS-M. (A) Volcano plot of RNA-seq values in LPS+IC condition as compared to LPS 
condition. In parentheses are the number of genes regulated above or below 2-fold change with a z-
score < 0.05. Highlighted in the box are the top most highly and significantly upregulated genes with 
their respective identities, sorted by log fold change (x-axis) and log p value (Y axis). (B) The top 
10 most highly upregulated and downregulated transcripts in LPS+IC stimulated macrophages 





upregulated significantly compared to resting cells. Within the 10 most down-regulated 
genes by R-M-IC were IL12B, a cytokine that induces Th1 responses, and CCL8, a 
chemokine that attracts monocytes. Both of these genes appeared in the list of top 10 
most upregulated genes in LPS-M (Figure 3B). Taken together, our data indicate that 
LPS stimulation triggers major gene expression variations in human macrophages. 
Addition of IC in conjunction with LPS leads to remarkable downregulation of 
inflammatory gene expression, shutting down the LPS-M markers and enhancing an 
array of immunoregulatory genes with probable roles in tissue modeling and 
angiogenesis. 
3.2 RNA and cell-surface biomarkers of human regulatory macrophages 
Markers for the identification of macrophages with regulatory functions in 
humans could be relevant to the discovery of prognostic markers for inflammatory 
diseases. For this reason, we employed three different approaches for the identification 
of potential biomarkers: (a) a fluorescence in situ hybridization method for the visual 
microscopic identification of R-M-IC, (b) flow cytometric identification of surface 
and intracellular markers, and (c) secretome analysis to define secreted markers. 
3.2.1 Markers of R-M-IC for imaging 
Three genes, IL-10, LIF, and MMP10, were chosen as potential RNA 
biomarkers based on their high fold-change in expression compared to both LPS-M 
and NS-M in the RNA-seq. Activated macrophages (NS, LPS, and LPS+IC) from 
three donors were fixed, and then stained using custom probes from Advanced Cell 





LPS+IC stimulated HMDMs for all 3 markers was significantly higher than the change 
in MFI induced by LPS treatment alone (Figure 5). Resting cells showed little to no 
expression of these transcripts. Combined with a macrophage marker, this method may 
prove useful for identification of R-Mϕ-IC in human tissue. 
3.2.2 Flow cytometry marker for R-Mϕ-IC 
 Flow cytometry is a powerful and sensitive measurement tool that allows the 
characterization of individual cells from both research animals and human patients. The 
development of a cell-surface biomarker of R-Mϕ-IC activation was thus a strong 
interest for us, as it would be useful as biomarker for flow cytometry and potentially 
for immunohistochemistry techniques for use in human tissue. Using the RNA-
sequencing data we identified genes that met the following criteria: (1) upregulated 
significantly with a minimum fold change of 2 in R-Mϕ-IC compared to LPS-Mϕ, (2) 
classified as a plasma membrane protein according to the Ingenuity Pathway Analysis 
database, and (3) having an average expression of at least 1 read per sample. The 
resulting list was sorted according to fold change between LI and LPS, and the top 
resulting genes were measured with flow cytometry. Several markers were tested that 
produced insignificant results, including TM4SF1, CD93, CD68, NOTCH2, GPR-
C5A, and CD49b (data not shown). Of the many proteins tested, CXCR4 (Figure 6A) 
and DC-STAMP (Figure 6B) were the most reliable predictors of R-Mϕ-IC activation. 
At 16 hours after activation of HMDMs, cells positive for CXCR4 increase 
significantly in R-Mϕ-IC over both LPS-Mϕ and NS-Mϕ (Figure 6C). For DC-STAMP 
both MFI and % positive cells increased significantly over LPS-Mϕ (p-value<0.05), 







Figure 5. RNAscope can be used to identify R-Mϕ-IC. Mean fluorescence intensity per cell for 3 
genes selected as potential RNA biomarkers using RNAscope, in Mϕ-NS (A), Mϕ-LPS (B) and R-
Mϕ-IC (C). Sample RNAscope images with LIF in green, MMP10 in red, and IL-10 in magenta. 
Mean intensity per cell from 3 donors was quantified using Zen Software and is expressed as fold 







Figure 6. CXCR4 and DC-STAMP are potential cell surface biomarkers for R-M-IC. HMDMs 
were stimulated with LPS with or without IC and collected 16 hours later for flow cytometry analysis 
of candidate biomarkers. Scatterplots are representative flow cytometry results for CXCR4 (A) and 
DC-STAMP (B). (C) % positive macrophages and MFI for both markers were calculated using data 
from multiple donors (n indicated in graphs; error bars are SEM, ** p-value<0.01). Figures were 





These data indicate that CXCR4 and DC-STAMP are potential cell surface biomarkers 
for R-Mϕ-IC.  
 In addition to upregulated transcripts, we also selected downregulated 
transcripts to test their potential as negative markers. Figure 7A shows the flow 
cytometry staining results for CD66b, also known as carcinoembryonic antigen-related 
cell adhesion molecule 8 (CEACAM8). Although LPS slightly downregulated this 
marker, LPS+IC significantly downregulated its expression compared to both LPS-Mϕ 
and NS-Mϕ (Figure 7B). Used together with CXCR4 and DC-STAMP upregulation, 
we proposed surface CD66b downregulation as a potential indicator of R-Mϕ-IC 
activation.  
3.2.3 Secretory protein markers of R-Mϕ-IC 
To characterize the secretome of R-M-IC, a SOMAscan assay was performed 
on cell culture supernatants of HMDMs collected 24 hours following stimulation. As 
previously observed, IC was able to suppress the production of inflammatory mediators 
that were significantly upregulated with LPS treatment (Figure 8A). ELISA was 
performed to validate on proteins of interest. Whereas IL-6 and IL-12p40 were 
significantly downregulated (Figure 8B), CXCL11 was not detectable (data not 
shown). IL-12p40 did not appear on the SOMAscan panel, but it was measured as well 
because it was previously demonstrated to be down-regulated by IC53. The CC- 
chemokines CCL8, CCL15, CCL19 and CCL23, and CXC- chemokines CXCL11, 








Figure 7. CD66b surface expression is suppressed by IC co-stimulation. HMDMs were 
stimulated with LPS with or without IC and collected 16 hours later for flow cytometry analysis of 
candidate biomarkers. (A) Representative histogram for CD66b staining from one donor. (B) MFI 
for CD66b was calculated using data from 5 donors (error bars are SEM, ** p-value<0.01). Figures 







   
Figure 8. Treatment with immune complexes broadly suppresses the inflammatory actions of 
LPS. Cell culture supernatants were collected from NS, LPS, and LPS+IC stimulated HMDMs 24 
hours after stimulation and differentially expressed proteins were identified using SOMAscan 
technology. (A) All extracellular proteins that were significantly upregulated in LPS-M compared 
to NS-M, but suppressed by R-M-IC treatment (log2 FC >1). (B) ELISA confirmation of 
inflammatory cytokines; IL-12p40 was included despite being absent from the SOMAscan panel. 
Data for figures were generated in collaboration with Stephen Christensen, Jingya Wang, Gary Sims, 






The proteins of the complement pathways C3, C4AC4B and CFB were also inhibited, 
indicating that addition of IC targets several pathways of inflammation for down 
regulation. 
Cyclic AMP (cAMP) is a second messenger known to be produced following 
prostaglandin E2141 and adenosine treatment142, both of which induce regulatory 
activation in LPS-stimulated murine macrophages53. Because cAMP can suppress 
cytokine production, it was hypothesized that cAMP levels may be increased in R-M-
IC as well. Measurement of cAMP with ELISA showed a significant increase in 
intracellular production of cAMP in macrophages stimulated with LPS+IC, with no 
detectable production apparent with LPS alone (Figure 9A). Attempts to block cAMP 
production using 3 different inhibitors of adenylyl cyclase were unsuccessful; however, 
treatment with forskolin (a drug that increases intracellular levels of cAMP) was able 
to suppress the LPS-induced production of inflammatory cytokines in HMDMs (Figure 
9B). 
To identify secreted proteins that are upregulated in R-M-IC, we followed two 
approaches (a) identify proteins that are specifically upregulated in R-M-IC and not 
under naïve or LPS stimulated conditions and (b) identify proteins that are >2 fold 
upregulated in R-M-IC compared to LPS stimulation (Figure 10A). Among the 
proteins upregulated >2 fold specifically by R-M-IC cells but not in LPS-stimulated 
cells were MMP-3, SPHK1, PRSS22, LBP and TNFRSF25. Secreted proteins that were 
triggered by LPS and are further upregulated by IC by >2 fold change include IL-10, 






Figure 9. IC treatment increases intracellular cyclic AMP, which has a suppressive effect on 
inflammatory cytokines. (A) Activated HMDMs were lysed 2 minutes following stimulation, and 
intracellular cAMP was then measured using a direct ELISA colorimetric assay (n=3, p-value<0.01). 
(B) HMDMs were stimulated with 30 ng/mL LPS for 16 hours with or without forskolin, a small-






Figure 10. Treatment with LPS and IC leads to significant increase in several proteins 
implicated in immunoregulation, tissue remodeling, and angiogenesis. Cell culture supernatants 
were collected from NS-M, LPS-M, and R-M-IC HMDMs 24 hours after stimulation and 
differentially expressed proteins were identified using SOMAscan technology. (A) All extracellular 
proteins which were significantly upregulated in R-M-IC compared to both resting and LPS-M, 
with corresponding levels from LPS-M included for comparison. (B) ELISA confirmation of 
several of the gene changes observed in SOMAscan results (n=5, *p-value<0.05, **p-value<0.01, 
***p-value<0.001). Data for figures were generated in collaboration with Stephen Christensen, 






IL-10, a well-defined marker for R-M39, was the second most highly upregulated of 
all proteins compared to LPS stimulation. For further verification, the expression of 
proteins that can serve as markers of secretory proteins of R-M-IC were validated by 
ELISA (Figure 10B) at 24 hours after stimulation. 
Fold changes in protein levels from the SOMAscan were compared to the 
corresponding genes from the transcriptome to determine whether changes in secreted 
proteins corroborate the transcriptional changes observed in the RNA-seq (Figure 11). 
A general positive correlation was observed, although the genes differed in the degree 
of fold change (r2 = 0.46). Nevertheless, the R value of 0.68 (p value = 0.0001) indicates 
a positive correlation between mRNA and protein regulation.  
For qRT-PCR studies, a 7-hour time point was chosen rather than the previously 
chosen 4 hour time point (used for the RNA-sequencing) because gene induction in R- 
M-IC for the biomarker panel was higher at 7 hours. From the 16 LI-associated 
upregulated genes from the SOMAscan data, 10 genes were chosen based on their 
ability to meet the 3 following criteria: (1) upregulated compared to NS at the mRNA 
level, (2) not upregulated during general cellular stress, and (3) mainly secreted, as 
quantified by a confidence level of 5 for secreted/PM and 3 or less for all other locations 
according to the GeneCard database. Quantitative real-time PCR of these 10 genes 
(Figure 12) was performed to develop a panel as a readout for mechanistic studies. For 








Figure 11. Correlation between protein and mRNA levels for differentially expressed proteins 
in R-M-IC. Fold changes of all differentially regulated proteins observed in SOMAscan results 
(LPS+IC vs LPS) plotted against fold changes observed in the RNA-seq for the corresponding genes. 







Figure 12. Quantitative real-time PCR validation of 10 chosen genes from the SOMAscan. qRT-
PCR confirmed that 10 genes chosen for a R-M-IC marker panel are reliably upregulated at the 





3.3 Bioinformatic analysis predicts MAPK-ERK, PI3K-Akt and AP1 complex as 
upstream regulators 
3.3.1 Ingenuity Pathway Analysis 
Identifying key molecular regulators of transcriptional programs is important 
for development of treatments that seek to activate the regulatory macrophage 
phenotype in vivo. To identify the key pathways and master regulators involved in 
generation of the R-Mϕ-IC phenotype, differentially expressed genes from RNA 
sequencing (R-Mϕ-IC vs LPS-Mϕ) were analyzed using the Ingenuity Upstream 
Regulators Analysis of the Ingenuity Pathway Analysis program (IPA). This analysis 
uses information available in the literature to predict upstream regulators of the R-Mϕ-
IC differentially expressed genes (DEGs) by identifying the presence of targets for 
specific regulators within the dataset. If there is significant overlap between the target 
dataset and the R-Mϕ-IC DEGs, and the direction of gene change is consistent with the 
action of the regulator, the regulator is predicted to be either activated or inhibited. The 
results of this analysis predicted MAPK kinases and Akt signaling pathway members 
to be probable regulators for the transcriptional gene changes in R-M-IC (Table 2).  
3.3.2 Gene Set Enrichment Analysis 
To complement the IPA analysis, we utilized GSEA to predict transcriptional 
regulators likely to be involved in induction of R-Mϕ-IC genes. RPKMs from LPS+IC 
and LPS RNA-seq samples were ranked according to difference between LI and LPS, 
and compared to transcription factor target gene sets. Each set contains genes that share 





Table 2. Ingenuity Pathway Analysis Upstream Regulators Report 
Upstream Regulator Molecule Type z-score p-value 
ERK group 4.451 1.20E-17 
ERK1/2 group 3.977 2.15E-17 
RAF1 kinase 5.084 5.86E-17 
PI3K (complex) complex 2.797 2.85E-12 
Ras group 3.299 1.53E-10 
AKT1 kinase 2.826 2.40E-10 
KRAS enzyme 2.88 3.43E-10 
MAP3K1 kinase 2.875 1.11E-09 
Ap1 complex 2.763 4.62E-09 
Pkc(s) group 4.165 1.28E-08 
________________________________________________________ 
Top 10 R-M-IC-associated activated regulators ranked by p-value. Differentially 
regulated genes in LI vs LPS were uploaded and analyzed in IPA using the Upstream 
Regulators Analysis. Results were filtered by removing regulators with a low number 
of targets in its target dataset (<10). To identify regulators consistent with intracellular 
cytosolic signaling molecules, results were filtered according to “molecule type’ to 
include only groups, kinases, complexes, and enzymes (removed extracellular 









the regions spanning up to 4 kb around their transcription start sites129. Listed in Table 
3 are the top 10 transcription factors ranked by normalized enrichment score; AP-1, a 
direct target of ERK, dominated the list. GSEA of curated gene sets identified overlap 
of the R-Mϕ-IC associated genes with genes upregulated in cancer and hypoxic 
conditions, both associated with activation of the Akt pathway (Table 4). The curated 
data sets contain data from various sources such as online pathway databases, 
biomedical literature, and knowledge of domain experts; it includes chemical and 
genetic perturbations, all canonical pathways, BioCarta gene sets, KEGG gene sets and 
Reactome gene sets128. Further down the list, it was observed that R-M-IC genes also 
significantly overlap with genes upregulated in breast cancer cells expressing a 
constitutively active form of Akt1. In light of these results, the Akt/ERK pathways were 
chosen for further mechanistic studies on gene expression in R-Mϕ-IC. 
 
3.4 Akt and ERK are activated in R-Mϕ-IC and contribute to immuno-regulatory gene 
induction 
3.4.1 Akt pathway antibody array 
To explore the results from the IPA Upstream Regulators Analysis, an antibody 
array for phosphorylated proteins in the Akt/ERK pathway was utilized on protein 
lysates from activated HMDMs 30 minutes after stimulation. LPS alone modestly 
activated several signaling proteins along this pathway, which were amplified by the 
addition of IC (Figure 13A). Figure 13B reveals the fold change compared to NS after 














Table 3. Gene Set Enrichment Analysis (C3: Transcription Factor Targets) 
Transcription Factor Name Size NES FDR q-val 
V$BACH2_01 BACH2 257 2.0635881 0 
V$AP1_01 AP1 249 1.9047545 0.009461368 
V$TATA_01 TATA 246 1.8897362 0.00872087 
V$BACH1_01 BACH1 249 1.8852448 0.00712926 
V$AP1_Q2_01 AP1 255 1.8239871 0.014296551 
V$AP1_Q6 AP1 245 1.7120004 0.03983329 
V$AP1_Q4 AP1 255 1.6929773 0.034499478 
V$PBX1_02 PBX1 124 1.6775415 0.03656478 
V$AP1_Q4_01 AP1 247 1.6308024 0.03817041 
TGASTMAGC_V$NFE2_01 NFE2 183 1.6269499 0.05723352 
V$RSRFC4_Q2 RSRFC4 199 1.6248336 0.05367498 
V$ATF_B ATF 184 1.6105359 0.050147545 
V$ATF1_Q6 ATF1 222 1.6081342 0.05381274 
V$AP1_Q6_01 AP1 255 1.5973284 0.051095504 
V$AP1_C AP1 259 1.5765415 0.054647822 
V$AP1_Q2 AP1 250 1.5457755 0.06257205 
V$AP1FJ_Q2 AP1 253 1.5270847 0.0778924 
V$OCT1_02 OCT1 202 1.5193005 0.08692873 
V$MEF2_Q6_01 MEF2 231 1.5178035 0.087893 
V$TATA_C TATA 271 1.5150462 0.08454026 
Top 20 R-M-IC-associated transcription factors ranked by normalized enrichment 
score (NES). Differentially regulated genes in LPS+IC vs LPS were analyzed in GSEA 
to predict transcriptional regulators likely to be involved in induction of R-Mϕ-IC 
genes. DEGs were compared to transcription factor target gene sets. Each set contains 
genes that share a transcription factor binding site defined in the TRANSFAC database 
(version 7.4) to determine degree of overlap. “Size” refers to the number of DEGs that 
appear in the gene set. FDR refers to the False Discovery Rate. Analysis performed by 
Jingya Wang. 









Table 4. Gene Set Enrichment Analysis (C2: Curated Gene Sets) 
Name Size NES 
FDR  
q-val 
Upregulated in NRG1 signaling 170 2.726674 <0.0001 
Upregulated by WT1 208 2.6159592 <0.0001 
Upregulated by EGF 56 2.598476 <0.0001 
Upregulated during hypoxia 125 2.5628119 <0.0001 
Metastasis by ERBB2 43 2.476098 <0.0001 
Downregulated by HIF1A and HIF2A 101 2.3819392 <0.0001 
HRAS oncogenic signature 244 2.32088 <0.0001 
Upregulated in hypoxia 163 2.3159282 <0.0001 
Upregulated in TGFB1 194 2.2986596 <0.0001 
Tumorigenesis 59 2.2963085 <0.0001 
Degraded via KHSRP 97 2.2956862 <0.0001 
Downregulated in adenovirus infection 40 2.292276 <0.0001 
Upregulated in basal vs luminal breast  52 2.2745335 <0.0001 
Peptide chain elongation 84 2.2740734 <0.0001 
Downregulated by CDH1 56 2.27238 <0.0001 
Methylated in breast cancer 35 2.262185 <0.0001 
Associated with epithelial differentiation 66 2.2621262 <0.0001 
Upregulated in hypoxia 47 2.2602153 <0.0001 
Transiently induced by EGF 465 2.2463908 <0.0001 
Upregulated by IL-2 signaling 109 2.2423522 <0.0001 
Top 20 curated gene sets overlapping with the R-M-IC gene signature, ranked by 
normalized enrichment score. “Size” refers to the number of R-M-IC DEGs that 
match genes in the associated dataset. Names have been edited for ease of reading. 









Figure 13. Immune complexes trigger increased phosphorylation of Akt, ERK, GSK3 and 
RSK1. (A) An Akt antibody array on whole cell lysates from HMDMs stimulated for 20 minutes 
containing antibodies against phosphorylated proteins of the Akt signaling pathway (Cell Signaling 






panel whose phosphorylation increased notably following co-stimulation with IC. 
Because Akt, ERK, GSK3 and GSK3β showed increased phosphorylation in R-M-
IC compared to LPS, they were selected for further analysis. Because RSK1 is directly 
downstream of ERK, its validation was delayed until it could be determined whether 
ERK or Akt were more potent regulators of the phenotype.  
3.4.2 Involvement of ERK in R-Mϕ-IC gene induction 
Western blotting of ERK kinases were performed to confirm the results of the 
antibody array. Consistent with our previous observation in mouse58, ERK 1/2 showed 
increased phosphorylation in LPS+IC treated cells (Figure 14A) with peak 
phosphorylation levels at 30 minutes (Figure 14B, n=3). Inhibition of ERK with U0126 
suppressed four of the ten marker genes, with MMP1, MMP3, serpine 1, and MMP10 
being significantly responsive to the effect of inhibition (Figure 14C). Because ERK 
only regulated a minority of the genes in the panel, the ERK substrate RSK1, despite 
displaying increased phosphorylation in the antibody array, was not chosen for further 
analysis.  
3.4.3 Involvement of Akt in R-Mϕ-IC gene induction 
Western blotting of phosphorylated Akt was performed to confirm the results 
of the antibody array. Phosphorylation of Akt at Threonine 473 was higher under 
LPS+IC treated conditions (Figure 15A representative blot), with phosphorylation 
levels peaking at 30 min (Figure 15B, mean densitometry for 3 blots from independent 







Figure 14. ERK is activated in R-M-IC and contributes to expression of LI-induced genes. 
(A) Western blot was used to confirm membrane array results in HMDM WCLs in the first 40 
minutes after stimulation. (B) Densitometry was calculated using ImageJ software and normalized 
to loading control. Results from 3 blots at the 30 minute timepoint were averaged and statistics were 
performed to measure significance (n=3, p-value<0.05). (C) HMDMs were stimulated for 7 hours 
with LPS+IC, with or without a small molecule inhibitor of ERK (U0126, 10 µM). Gene expression 







Figure 15. R-M-IC display increased activation of Akt, which contributes to LI-induced gene 
changes.  (A) Western blot was used to measure phosphorylation of Akt at thr473 30 minutes after 
stimulation with LPS+IC. (B) Densitometry on 3 replicate blots was calculated using Image J 
software and normalized to the loading controls. (C) R-M-IC were treated with an inhibitor of Akt 
(MDS12384) before stimulation, and gene expression was measured at 7 hours using qRT-PCR (n=4, 
*p-value<0.05, **p-value<0.01, ***p-value<0.001.) Fold change was calculated using LPS and 





To determine the involvement of the Akt pathway on gene expression in R-M-
IC, the macrophages were treated with an inhibitor of Akt and the mRNA levels of the 
R-M-IC markers (see Figure 12) were quantified by qRT-PCR. Akt inhibition 
suppressed LI-induced expression of 8 of the 10 genes (Figure 15C). This was not likely 
due to any non-specific effects of the inhibitor, as inhibition of Akt led to varied effects 
on these genes in LPS-stimulated cells (Figure 16). Together, the data identify the 
MAPK-ERK and PI3K-Akt pathways as the primary pathways that drive regulatory 
phenotype in macrophages, with Akt being strongly influential. 
3.5 GSK3 inhibition upregulates expression of R-Mϕ-IC markers 
Although GSK3 was not identified as one of the transcriptional regulators by 
GSEA analysis, the phosphorylation pattern of this protein was observed to be higher 
in the antibody array (Figure 13). Furthermore, the z-score for GSK3β from the IPA 
upstream regulators analysis was -1.862, indicating that its activity is predicted to be 
inhibited in these cells. Previous studies have demonstrated an inhibitory role for Akt 
on GSK3 signaling143, and that GSK3 inhibition is known to increase IL-10 expression 
in primary human macrophages105. This led us to hypothesize that activation of Akt by 
IC should negatively regulate GSK3 and thus lead to higher IL-10 secretion. 
3.5.1 GSK3 inhibition phenocopies IC co-stimulation 
First, an ATP-competitive inhibitor of GSK3/ was used in lieu of IC to 
determine if the GSK3 inhibition together with LPS stimulation could induce some of 
the transcripts that were induced in R-Mϕ-IC cells.   Combined with LPS, the GSK3 

































































Figure 16. Akt inhibition has varied effects on M1 activation and does not broadly suppress 
gene expression. LPS-stimulated macrophages were treated with an inhibitor of Akt (MDS12384) 
15 minutes prior to stimulation and gene expression was measured at 7 hours using qRT-PCR. Values 







RNA markers for LPS+IC, 7 of which achieved statistical significance (Figure 17A). 
Interestingly, the inhibitor did not affect expression of inflammatory cytokines (Figure 
17B) indicating that GSK3 inhibition is important for inducing regulatory genes 
expression, but is not sufficient for inhibiting LPS-triggered inflammatory response. 
To determine if a GSK3β-specific inhibitor could also induce an anti-
inflammatory response, and if the response could be observed at the protein level, the 
small-molecule inhibitor AZ2848 was used in combination with LPS to activate 
HMDMs. ELISA analysis found that GSK3β-specific inhibition significantly 
upregulated IL-10 and MMP10 in these cells (Figure 18). MMP-1 levels were also 
upregulated, but this increase was not statistically significant due to extreme variability 
in donor response. This variability for MMP-1 at the protein level was also observed in 
response to LPS+IC (Figure 10B). LIF and MMP-12 were also measured by Luminex, 
but neither one was detectable above threshold in most samples. Both genes had low 
transcript numbers in the RNA-seq, which may explain why they were undetectable at 
the protein level.  
3.5.2 Co-stimulation with IC prevents entry of GSK3β into the nucleus 
To validate the results of the antibody array, a western blot on phosphorylated 
GSK3β was performed (Figure 19). Although phosphorylation of GSK3 was observed 
after both LPS and LPS+IC stimulation, there was only a moderate increase for LPS+IC 
above LPS, which was not significant (Figure 19A). Because GSK3β shuttles between 
the cytoplasm and the nucleus, and active GSK3β has been shown to accumulate in 







Figure 17. GSK3β inhibition phenocopies IC co-stimulation. (A) HMDMs were stimulated with 
LPS, LPS+IC, or LPS in the presence of a small molecule inhibitor of GSK3, SB415286 (20 µM). 
RNA was collected 7 hours after stimulation for qRT-PCR analysis of mRNA transcript levels (fold 
change is over NS, n=4, bars are standard error of the mean, *p-value<0.05, **p-value<0.01, ***p-
value<0.001). (B) Production of inflammatory cytokines 8 hours after stimulation measured by 






Figure 18. GSK3β-specific inhibition increases protein levels of R-M-IC markers. HMDMs 
were stimulated with LPS or LPS in the presence of AZ2848, a β isoform-specific inhibitor of GSK3 
(750 nM). Supernatants were collected 16 hours after stimulation and analyzed using ELISA (for IL-







Figure 19. IC co-stimulation inhibits entry of GSK3 into the nucleus. (A) Western blot for 
phosphorylated GSK3 in whole cell lysates, 30 minutes after activation. (B) Western blotting for 
total GSK3 in the nuclear and cytosolic fractions of protein lysates collected 30 minutes after 
stimulation. (C) Densitometry on 3 replicate blots from (B) was calculated using Image J software 
and normalized to the loading controls before calculating ratio between nuclear and cytosolic GSK3 





lysates. The western blot revealed that while LPS stimulation led to an increase of 
GSK3β in the nucleus, co-stimulation with IC prevented nuclear translocation, bringing 
levels down to even lower than those observed in resting cells (Figure 19B). 
Densitometry analysis (Figure 19C) found this decrease in levels compared to LPS to 
be statistically significant (n=3, p-value<0.05). 
3.6 IPA Diseases and Functions Analysis implicates pathways associated with growth 
To determine the functional significance of the differentially expressed genes 
in R-Mϕ-IC, we uploaded the RNA-seq fold change values from the LPS+IC group 
compared to LPS treated group into the Ingenuity Pathway Analysis program. The 
Diseases and Functions report from IPA indicated an up-regulation of genes involved 
in angiogenesis, proliferation, and tumor vulnerability (Figure 20A), and a down 
regulation of genes associated with inflammation (Figure 20B). Because the nature of 
the functions was similar, all predicted functions with a z-score greater than 2 or less 
than 2 were manually sorted into broader categories (Figure 20, pie charts). Since the 
diseases and functions available in the IPA knowledge database are based on available 
literature, the pie charts should be interpreted only as a summary of the functions that 
have been predicted, and should not be taken to indicate the proportion of gene changes 
associated with a particular function.  
Because even significant overlap in genes can occur between two predicted data 
sets, the number of unique genes that predicted the 43 activated functions was 
determined. In total, 1,337 unique genes contributed to the predicted upregulated 
functions, 754 of which occurred in three cases or fewer. A total of 54 genes were 







Figure 20. RNA sequencing reveals significant changes in global mRNA expression related to 
immune regulation, angiogenesis, and cancer in R-M-IC. All DEGs in LI vs LPS, both 
significantly up and down regulated (FC >=2 or <= -2) were uploaded into the Ingenuity Pathway 
Analysis Program by Qiagen, and the Diseases and Functions Report was generated. The bar graph 
represents the top 20 most significantly upregulated (A) and downregulated (B) functions, ranked 
by z-score. To simplify the visualization, all diseases and functions predicted to be regulated were 






contributing to the prediction of 33 downregulated functions. 306 of these genes appear 
in 3 or fewer function data sets, while 48 genes occur in more than half of the 
downregulated functions. IL-10 appeared in 30 out of the 33. The minimum number of 
LI-associated genes that contributed to the prediction of a function (up or 
downregulated) was 38 (invasion of malignant tumor), and the maximum was 1,290 
(Cancer). The number of genes used to predict each function is listed in Table 5 along 
with p-value and z-score. 
These predictions are supported by the results of the gene set enrichment 
analysis (GSEA), which was dominated by gene sets associated with cancer or 
associated pathways, such as growth factor signaling and hypoxia (Table 4). The IPA 
analysis suggests a pro-survival, pro-growth, and anti-inflammatory phenotype in the 







Table 5. Ingenuity Pathway Analysis Diseases and Functions Report 
Diseases or Functions Annotation p-Value 
Activation 
z-score # Molecules 
invasion of tumor 1.77E-11 4.365 53 
invasion of malignant tumor 7.59E-11 3.651 38 
synthesis of lipid 9.67E-12 3.64 118 
cell survival 8.76E-26 3.498 201 
organization of cytoskeleton 3.02E-17 3.445 218 
organization of cytoplasm 2.42E-15 3.445 228 
invasion of cells 1.91E-21 3.268 141 
cell viability 3.50E-23 3.26 176 
development of cardiovascular system 7.99E-18 3.172 193 
angiogenesis 4.67E-18 3.079 164 
vasculogenesis 6.51E-16 3.032 136 
microtubule dynamics 1.11E-10 3.019 168 
proliferation of cells 1.27E-34 2.867 518 
invasion of tumor cell lines 1.30E-13 2.763 80 
growth of tumor 1.67E-24 2.702 157 
head and neck cancer 7.81E-12 2.668 111 
quantity of cells 3.78E-30 2.658 312 
formation of cells 3.09E-13 2.592 160 
differentiation of hematopoietic progenitor cells 2.04E-10 2.536 62 
migration of tumor cells 8.91E-14 2.476 55 
growth of epithelial tissue 4.11E-19 2.418 136 
differentiation of bone 6.39E-09 2.369 71 
viral infection 7.73E-12 2.341 163 
cancer 1.44E-38 2.337 1290 
differentiation of hematopoietic cells 1.14E-10 2.332 64 
differentiation of cells 2.15E-28 2.297 362 
formation of cellular protrusions 4.38E-11 2.277 139 
mammary tumor 1.36E-12 2.242 236 
breast cancer 1.08E-11 2.224 219 
growth of neurites 5.48E-09 2.197 77 
development of body trunk 2.95E-12 2.19 167 
central nervous system tumor 2.58E-09 2.166 132 
endothelial cell development 1.62E-11 2.141 70 
proliferation of fibroblasts 1.34E-10 2.12 67 
migration of cancer cells 2.33E-12 2.107 47 
cell movement of tumor cells 1.91E-11 2.104 44 
synthesis of DNA 2.88E-11 2.1 73 





growth of connective tissue 1.96E-19 2.07 132 
cell cycle progression 2.67E-15 2.06 153 
cell movement of fibroblasts 4.87E-09 2.037 39 
growth of plasma membrane projections 6.93E-10 2.033 80 
metabolism of eicosanoid 1.79E-10 2.012 49 
infiltration of cells 6.47E-21 -2.053 98 
lymphocyte migration 2.07E-14 -2.059 75 
inflammation of liver 4.76E-12 -2.064 59 
hypertrophy of heart 3.66E-12 -2.072 69 
infiltration by mononuclear leukocytes 9.03E-10 -2.073 40 
immune response of phagocytes 3.02E-15 -2.088 52 
dermatitis 3.33E-12 -2.09 84 
quantity of IgG 1.40E-14 -2.103 56 
cell death of tumor cell lines 7.62E-13 -2.134 92 
hypoplasia 2.45E-09 -2.139 86 
cell death of hematopoietic progenitor cells 1.17E-12 -2.16 52 
response of phagocytes 6.85E-14 -2.206 53 
chronic inflammatory disorder 3.43E-19 -2.267 177 
rheumatoid arthritis 1.17E-15 -2.319 130 
rheumatic disease 2.12E-17 -2.343 184 
apoptosis of hematopoietic progenitor cells 1.73E-12 -2.404 48 
hypersensitive reaction 6.92E-13 -2.414 85 
arthritis 1.49E-17 -2.43 170 
arthropathy 3.67E-17 -2.468 171 
cell death 2.09E-26 -2.469 449 
apoptosis of tumor cell lines 3.52E-12 -2.482 76 
apoptosis 4.57E-27 -2.579 379 
glucose metabolism disorder 1.97E-09 -2.643 182 
seizure disorder 1.94E-12 -2.651 89 
inflammation of respiratory system component 1.58E-14 -2.709 83 
necrosis 2.17E-29 -2.905 347 
inflammation of respiratory system 3.82E-15 -2.982 85 
seizures 5.77E-14 -3.027 83 
inflammation of lung 6.55E-13 -3.168 76 
inflammation of body region 5.14E-26 -3.221 190 
inflammation of body cavity 1.44E-18 -3.312 135 
inflammation of organ 2.60E-25 -3.71 217 
organismal death 4.75E-15 -7.687 338 
Diseases and functions predicted to be up- or down-regulated in R-M-IC, ranked 
by z-score. DEGs in LI vs LPS were uploaded and analyzed in IPA using the 
Diseases and Functions analysis. “# Molecules” refers to the number of DEGs in 





3.7 The effect of GSK3 inhibition on lethal endotoxemia 
In previous studies, murine BMDMs pre-treated with LPS and IC were able to 
rescue mice from lethal endotoxemia53, an effect thought to be due in part to the high 
production of IL-10 secreted by these macrophages. To assess whether similar anti-
inflammatory activity could be induced by GSK3β inhibition in macrophages, we 
sought to utilize the same model. Unfortunately, treatment of BMDMs with GSK3 
inhibitor did not result in a drastic increase in IL-10 as was previously observed in 
HMDMs (Figure 21), despite looking at different time points (Figure 21A), different 
concentrations of inhibitor (Figure 21B), or different inhibitors (Figure 21C). Because 
of this, C57 black 6 mice were instead injected intraperitoneally with HMDMs that had 
been pre-treated with LPS, with or without a GSK3β-specific inhibitor. This injection 
was followed 2 hours later by injection of a lethal dose of endotoxin, and mice were 
then monitored for survival. In the mice injected with cells pre-treated with LPS, only 
70% had survived by 4 days, whereas mice injected with the LPS+GSK3 inhibitor 
treated cells survived at a rate of 100% (Figure 22). However, as the p-value was only 
























































Figure 21. GSK3β inhibition induces only a slight increase in IL-10 in murine macrophages. 
BMDMs derived from C57bl/6 mice were treated with LPS with or without an inhibitor of GSK3. 
(A) Time course of IL-10 secretion in BMDMs treated with two small-molecule inhibitors of GSK3 
(5 µM for each). (B) IL-10 production with GSK3 inhibition at various concentrations, 16 hours after 
stimulation. (C) BMDMs were treated with LPS and a potent GSK3β-specific inhibitor (600 nM) 
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Figure 22. The effect of macrophage-mediated GSK3β inhibition in lethal endotoxemia. 
C57bl/6 mice were injected with 2x105 HMDMs pre-treated for 1 hour in culture with 30 ng/mL 
LPS (circles), or LPS and GSK3 inhibitor (squares), followed by injection with a lethal dose of 
endotoxin two hours later. Graph represents 10 mice per group, with data pooled from 2 independent 





Chapter 4: Discussion 
 Previous studies of mouse macrophages  found that IC co-stimulation could 
not only suppress IL-12p40, but  also increase production of IL-10 and HB-EGF54,56,57. 
This led to the hypothesis that this activation state may play a critical role in tissue 
repair and the resolution of inflammation.  Indeed, injection of LPS+IC stimulated 
macrophages was able to rescue mice from lethal endotoxemia53. These so-called 
“regulatory” macrophages (R-Mϕ-IC) have a high therapeutic potential, but relevance 
in humans was still unknown. Using a combination of bioinformatics and functional 
analyses we have performed the first detailed characterization of this “activation state” 
in primary human macrophages. Our study proposes that this activation state plays a 
role in the regulation of inflammation, and that the Akt/GSK3 pathway has an integral 
part in this activity. 
Immune complexes are antigen-IgG antibody complexes used to study the 
effect of Fc receptor cross-linking in cell culture. Although these complexes do arise 
naturally within the body under some circumstances, especially in pathological 
conditions such as lupus, Fc receptor cross-linking is also normally induced in 
macrophages that have encountered pathogens opsonized with IgG.  These IgG 
molecules cross-link Fcγ receptors and facilitate not only the binding but also the 
internalization and intracellular fate of IgG-opsonized particles.  Here we show that 
regulatory macrophages have an anti-inflammatory mRNA profile in HMDMs and that 
IC co-stimulation increases production of molecules involved in healing, survival, and 
proliferation. This implicates a feedback mechanism wherein antibody production 





the resolution of inflammation and tissue remodeling through its effect on macrophage 
polarization. This idea is supported by a study examining the immune response to 
chlamydia in B-cell deficient mice, which found that B cells prevented an exaggerated 
immune response to the infection through induction of immunoregulatory cytokines 
145.  Another study found antibodies to be important in the wound healing response 
through direct binding of antibodies to damaged tissue 146. The idea that B cells could 
contribute to tissue healing is an idea that is rarely considered, and has been largely 
unexplored; nevertheless, some data exists to suggest adaptive immune responses is 
involved in proper wound healing following inflammation and damage147–150. Further 
studies are needed to uncover the mechanism underlying this observation, to determine 
the physiological relevance of the R-M-IC phenotype in vivo, and to identify the 
circumstances under which this phenotype occurs.  
 
4.1 Transcriptomic analysis 
As expected, stimulation of human primary macrophages with LPS led to the 
differential regulation of several thousand genes. The positive association between the 
two groups compared in Figure 3 indicates that the effect of LPS is similar in both LPS-
M and R-M-IC. Although LPS had a much greater influence on gene expression than 
did the addition of IC, immune complexes regulated over 1,000 transcripts. IC can 
influence LPS-regulated genes in several ways, including amplification or suppression 
of LPS-induced genes, or restoring suppressed genes to their baseline levels. This 
ability for IC to modulate LPS-induced gene changes is especially evident when 





inflammation. Despite less than 700 genes being downregulated in R-M-IC versus 
LPS-M, the addition of IC is able to significantly suppress these highly inflammatory 
LPS-induced transcripts at the RNA level.  
R-M-IC activation leads to the upregulation of 925 transcripts over LPS, 632 
of which are also upregulated significantly compared to resting cells. This latter 
distinction is important for the identification of genes most likely to serve as 
appropriate biomarkers and that may give this phenotype functional significance. The 
fact that many of these genes are associated with healing, angiogenesis, and resolution 
of inflammation led us to consider the possible role of these macrophages in tissue 
repair. TM4SF1, the most highly upregulated, is a transmembrane protein mainly 
studied in the context of cancer due to its effect on proliferation and migration of 
cells151. MMP10, also known as stromelysin-2, is a matrix metalloproteinase that has 
anti-inflammatory effects in vivo152,153 and is upregulated in ovarian and gastric 
cancer154,155. Table 6 lists the names and functions of some of the top most upregulated 
genes from Figure 4 that have a potential role in immune regulation. The functional 
associations of these genes and many others upregulated in R-M-IC was later 
confirmed by bioinformatics analyses on gene ontology, both with IPA and GSEA, 






Table 6. Known immunoregulatory functions of DEGs upregulated in R-M-IC 
Molecule Log2 FC vs LPS Functions 
TM4SF1 
Transmembrane 4 L six family 
member 1  Induces proliferation and migration of cells151 
MMP10 Matrix metallopeptidase 10   
Extracellular enzyme with anti-inflammatory 
activity152,153 
LIF Leukemia inhibitory factor 
Pleiotropic cytokine that influences survival and 
proliferation dependent on cell type156 
XIRP1 
 
Xin actin-binding repeat 
containing 1  Involved in muscle repair and regeneration157 
MMP3 Matrix metallopeptidase 3  
 
Involved in scar formation, tissue healing, and 
suppression of inflammation158–160 
GPR3 G protein-coupled receptor 3 Involved in cell survival and thermogenesis161,162 
MMP-1 Matrix metallopeptidase 1 
Degrades ECM; involved in tissue remodeling and 
metastasis163,164 
TNFSF14 
Tumor necrosis factor 
superfamily member 14 
Induces proliferation/differentiation165; involved in 
recovery after inflammation166 
IL-10 Interleukin 10 





Regulates of osteoclast differentiation167; increases 
survival of cancer cells168 
ANGPTL4 Angiopoietin-like 4 
Angiogenic molecule, involved in wound-healing 




Inhibin beta A 
 
 
Forms the homodimer Activin A; pro-wound 
healing and scar formation, induces regulatory T-









4.2 Biomarker identification and validation 
In order to determine the true physiological role of the R-M-IC phenotype, 
several specific biomarkers amenable to multiple measurement techniques must be 
identified and validated for use in human samples. Although biomarkers for regulatory 
activation have been identified in mouse, the response to LPS and immune complexes 
does not overlap 100% between the two species, necessitating species-specific markers. 
For example, CCR1 was identified as a regulatory marker for murine regulatory 
macrophages53, but CCR1 transcript levels were not similarly increased in human R-
M-IC, and were actually decreased compared to resting cells. Here we have identified 
potential markers of R-M-IC in HMDMs suitable for two well-known methods of 
measurement from human samples. 
4.2.1 RNAscope markers 
To provide a proof-of-concept for identification of these macrophages in tissue, 
we utilized RNAscope technology, which uses transcript hybridization with fluorescent 
probes to visually quantify transcripts within fixed tissue and cell culture samples. We 
found that IC-induced regulatory macrophages can be identified through increased 
expression of IL10, LIF, and MMP10 transcripts in HMDMs using this technology. 
Fluorescence intensity appeared to be very high in positive cells whereas other cells 
remained negative. This heterogeneity may be explained by the requirement for dense 
clustering of the Fc receptors to induce Syk activation171, which may not be above 
threshold in every cell.  If used in combination with a macrophage marker such as 
CD68, we propose this method for identification of regulatory macrophage activation 





4.2.2 Flow cytometry markers 
The identification of protein biomarkers for macrophage activation states 
represents a challenge due to the dynamic and transient nature of macrophage 
activation. In this study, we used RNA-sequencing to identify genes for plasma-
membrane associated proteins that have a very high fold change increase in R-M-IC. 
Due to the complex nature of macrophage activation it is unwise to rely on a single 
marker, and so a panel of markers, including both up- and down-regulated proteins, is 
ideal to develop a “signature” for R-M-IC activation. Through trial-and-error, flow 
cytometry studies showed that increased CXCR4 and DC-STAMP, along with 
suppressed CD66b expression were reliable cell surface markers for R-M-IC 
activation in human macrophages. Further studies are needed to validate these markers 
in human tissues.  
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) is a cell surface 
protein that, despite its name, is expressed also on stimulated macrophages. This 
protein is mostly known for its role in the regulation of osteoclast differentiation167, but 
also appears to increase survival in cancer cells168.  DC-STAMP has been shown to be 
regulated by ERK172, which may explain why its expression is sometimes increased in 
LPS-stimulated cells, but does not appear to be affected by GSK3 inhibition (data not 
shown).  
C-X-C chemokine receptor type 4 (CXCR-4) is CXC chemokine receptor that 
binds CXCL4 and is most well-known for its role in the cellular entry of the HIV virus 
into T cells, as well as its involvement in the recruitment of lymphocytes. CXCR4 is 





macrophage inhibitory factor (MIF)173 and extracellular ubiquitin, the latter of which 
is thought to have an anti-inflammatory effect174. CXCR4 expression is associated with 
the presence and actions of tumor associated macrophages175, as well as the 
immunosuppressive phenotype in macrophages seen after sepsis that increases risk for 
cancer growth176. Regulation of CXCR4 expression have been shown to be controlled 
by calcium signaling177 and cAMP178, both of 
which are thought to be increased after Fc receptor 
cross-linking in macrophages. As GSK3 
inhibition did not increase cell surface levels of 
CXCR4 (data not shown), this marker is likely 
controlled through other upstream regulators.  
CD66b, also known as CEACAM8, is a 
GPI-anchored cell surface protein involved in cell 
adhesion and activation of neutrophils, 
eosinophils and basophils179,180. Very little is 
known about its function in macrophages, but 
since it is a marker for granulocytes, it is suggested 
that this marker be used only in conjunction with 
a macrophage marker such as CD68. Similar to IC 
treatment, GSK3 inhibition also suppressed 
production of CD66b (Figure 23).  
Further studies are needed to validate the 
utility of these markers in human tissue, to (1) 
Figure 23. GSK3 inhibition 
suppresses the surface expression 
of CD66b. HMDMs were stimulated 
with LPS with or without GSK3 
inhibitor and collected 16 hours later 
for flow cytometry analysis of 
candidate biomarkers. MFI for 
CD66b was calculated using data 
from 3 donors. Figure was generated 





assess stability to ensure that the markers are not easily regulated by otherwise 
inconsequential changes in the environmental milieu; (2) to confirm that expression is 
induced relatively early and is sustained for a prolonged period; (3) to confirm that 
expression coincides with the expression of immunoregulatory proteins;  (4) to ensure 
that expression is observed in all types of tissue macrophages (microglia, osteoclasts, 
etc.) that are capable of undergoing regulatory activation; (5) to ensure that markers are 
not expressed with IgG antibody alone; (6) to determine if the expression is reliant on 
the use of LPS or if the marker can be upregulated in the presence of other TLR ligands 
or inflammatory cytokines; (7) to determine which upstream regulators (ERK, Akt, 
GSK3, calcium, cAMP, etc) control expression of each marker. Experiments that assess 
the ability for the potential biomarkers to meet these criteria will strengthen the 
recommendation for their use in explorative studies in human tissue.  
4.3 SOMAscan analysis of secreted proteins 
The results of the SOMAscan analysis largely verified our overall impressions 
from the RNA-sequencing results. Immune complexes are able to broadly suppress 
several LPS-induced cytokines and chemokines, an observation that may be explained 
by the upregulation of cyclic AMP in this phenotype. Cyclic AMP is a nucleotide that 
acts as a second messenger, and in macrophages has been observed to regulate 
cytokines through its activation of cAMP-response element binding protein (CREB). 
Here we’ve shown that cyclic AMP is highly upregulated within minutes of stimulation 
with immune complexes. This effect of FcR ligation has been previously observed, as 
treatment of neutrophils with immune complex was also shown to increase cAMP 





intracellular levels of cAMP, was able to suppress LPS-induced cytokines, suggesting 
that the ability for IC to suppress inflammatory cytokines could be mediated through 
production of cyclic AMP.  
The SOMAscan analysis also confirmed the ability for R-M-IC to produce 
high amounts of secreted soluble mediators, as shown by a drastic increase in high-
count proteins such as the MMPs. The work herein suggests a panel of proteins may be 
most appropriate for ELISA markers of this phenotype, with IL-10, MMP-1, and 
activin A being the most abundant. The upregulation of several matrix 
metalloproteinases suggests that regulatory macrophages could contribute to cell 
motility, angiogenesis, and tissue remodeling in the context of inflammatory stimuli. 
The increase in matrix metalloproteinases in particular could have a significant 
physiological impact, as MMPs are involved not only in degradation of ECM 
components, but also regulate extracellular signaling molecules137. MMP-10 
production by macrophages regulates and suppresses immune response following 
infection152,153, while MMP-3 and MMP-1 can cleave bFGF and VEGF, releasing their 
active forms. Not surprisingly then, MMP-1, MMP-3 and MMP-10182 are associated 
with tumor metastasis and angiogenesis. Given these actions, regulatory macrophages 
could inhibit immune responses at the site of inflammation and contribute to resolution 
and repair. Concordantly, activators of this phenotype could have a deleterious effect 
on cancer. We look forward to future studies that explore the role of this phenotype in 





4.4 Pathway analysis and validation 
Identifying the major players involved in functional phenotypic switches in 
activated macrophages is central to our understanding of inflammatory processes. 
Through our bioinformatics analysis, we found that the upregulated LI genes are 
associated with HIF, growth factor, Akt/PI3K and ERK signaling pathways. Very little 
has been done to test Ingenuity Pathway Analysis in its ability to accurately predict 
upstream regulators. However, the presence of obviously irrelevant regulators such as 
pharmaceutical drugs on the resulting list of potential regulators suggests that the false 
positive rate is very high. Another example of a likely false positive is the prediction 
of TREM1 activation. This receptor appeared several times in the upstream regulators 
predictions, both in IPA and GSEA. However, the downstream signaling of TREM1 is 
known to be mediated by ERK, a kinase also found to be activated in R-M-IC through 
cross-linking of FcRs. This provides a cautionary tale for investigators attempting to 
draw solid conclusions from bioinformatics data; until an analysis that can accurately 
predict an aggregated upstream pathway is designed, the prediction of these upstream 
regulators must be approached with skepticism. 
4.4.1 ERK 
In previous studies using mouse macrophages, ERK phosphorylation led to 
transient chromatin remodeling at the IL-10 promoter, which is what accounted for 
increased production of IL-10 seen after IC treatment 58. This knowledge was useful 
during our bioinformatics analysis, as the prediction of ERK involvement gave 
credence to the software’s ability to predict pathways and regulators involved in the 





macrophages, and inhibition of ERK suppressed the induction of 4 out of the 10 LI 
marker genes. However, IL-10 did not appear to be affected by ERK inhibition, which 
is inconsistent with previous results seen in murine macrophages53. Nevertheless, the 
involvement of ERK activation in this phenotype was also supported by a GSEA 
transcriptional targets analysis which predicted an increase in the activity of AP-1. AP-
1 is a transcription factor complex which regulates IL-10 and other LI-associated genes, 
and which is known to be directly activated by ERK183. However, because ERK did 
not regulate all of the 10 LI marker genes, further studies must be conducted to 
determine the major transcriptional drivers of the phenotype. 
4.4.2 Akt 
The upstream regulator analysis provided by IPA was the first to suggest the 
involvement of the Akt pathway in this phenotype. The Akt pathway is a complex 
signaling cascade that is remarkably sensitive to the nutritional status of the cell, and 
can regulate metabolism based on nutrient availability184. Akt is also activated by 
exposure to growth factors, and contributes to survival, increased glucose metabolism, 
proliferation, transcription factor activation, and in the case of macrophages, cytokine 
production185. Extracellular signaling molecules such as growth factors lead to 
activation of Akt through their effect on PI3K, which directly phosphorylates Akt186. 
Fc receptor cross-linking is also known to activate PI3K187, so the increased activation 
of Akt in the LPS+IC stimulated cells was not entirely unexpected. The effect of Akt 
inhibition on R-M-IC biomarkers was striking, as it was clearly involved in the 





upstream of so many pathways, it became important to determine which Akt substrate 
was responsible for the gene changes observed in our phenotype. 
4.4.3 GSK3 
GSK3 is a signaling kinase that is constitutively active in the cell, only 
becoming inactivated through phosphorylation of its substrate binding site101. It was 
first discovered by studying its effect on glycogen synthase, but was later found to 
phosphorylate dozens more molecules within the cell103. It became heavily studied in 
the area of neuroscience after it was discovered that lithium worked through inhibition 
of this kinase. Even more recently, GSK3 was found to have anti-inflammatory 
activity; in fact, IV injection of the small molecule GSK3 inhibitor SB216763 has been 
shown to increase survival of endotoxemia in mice188. When we observed that IC may 
increase phosphorylation of GSK3β, we hypothesized that GSK3 was involved in the 
ability for IC to regulate transcription. Through the use of the small molecule GSK3 
inhibitor SB415286, we found that GSK3 inhibition copied the LPS+IC phenotype 
without also increasing production of inflammatory cytokines. The ability for IC to 
drastically reduce the levels of GSK3β in the nucleus has a number of implications in 
transcriptional regulation. GSK3β is itself a transcription factor known to interact with 
AP-1, CREB, and NFκB, among others103, and is also involved in the regulation of 
chromatin remodeling189. GSK3β has been found to have an inhibitory effect on AP-1 
and CREB, both of which are involved in IL-10 transcriptional control 105,190. Although 
GSK3 is now known to be an important regulator of IL-10 in macrophages, this is the 
first study to show that GSK3β inhibition significantly amplifies LPS-induced 





inflammation, these findings may also explain previous observations that GSK3β 
inhibition is involved in wound healing and angiogenesis191,192.  
Although further attempts were made to validate the GSK3β phosphorylation 
seen in the results of the antibody array, only a slight increase in phosphorylation was 
observed. However, nuclear levels of GSK3β were significantly suppressed by IC co-
stimulation. Akt has been shown to inhibit entry of GSK3β into the nucleus144. The 
mechanism for regulation of nuclear translocation has not been thoroughly examined, 
but one study found that GSK3β contains a bipartite nuclear localization sequence that 
is normally blocked by the sequestration of GSK3β within protein complexes193. 
Interestingly, this study found that inhibitory phosphorylation at serine 9 was not 
sufficient to prevent nuclear translocation. Further studies using overexpression of 
GSK3β are needed to confirm the requirement for GSK3β inhibition for gene regulation 
following Fc receptor ligation, and to determine the mechanism by which this nuclear 





4.4.4 Proposed pathway  
Previous studies in mouse established the ability for immune complex to 
modulate the actions of LPS, generating an anti-inflammatory phenotype that relies on 
dual signals. In mouse, it was the activation of ERK, as opposed to other MAP kinases, 
that was able to generate this response. Here we propose that pathways that are 
minimally or inconsistently activated by TLR signaling (Akt and ERK) are amplified 
in the presence of IC, thus selectively amplifying the production of TLR-induced 
immunoregulatory genes. Until thorough studies are done delineating the pathway, the 
cause-and-effect relationships between these modulators can only be proposed. Given 
our previous studies in mouse and prevailing 
evidence in the literature, it is proposed that Akt 
activation is responsible for GSK3 inhibition in R-
Mφ-IC, and that this inhibition allows the 
independently activated ERK to upregulate 
immunoregulatory transcripts, possibly through 




4.5 In vivo relevance 
The effect described in this project can be induced by a wide range of 
biologically relevant substrates. In the past, it was found that IC can modulate the 
actions of other activators of classical inflammatory pathways in macrophages such as 






LTA (a TLR2 agonist) and CD40194. Furthermore, the second signal required to 
modulate inflammation needn’t be immune complexes specifically, but rather anything 
that induces FcγR cross-linking, or theoretically, anything that activates Akt1. Thus, 
any activator of the Akt1 pathway, such as growth factors, may also act in a similar 
manner. Delineating the pathways relevant in this phenotype has expanded the potential 
physiological relevance of our findings to any context that involves the combination of 
inflammatory stimulus with modulators of the Akt1/GSK3 pathway. 
The effects of low-level inflammation are considered a major driver of chronic 
disease in the developed world. Furthermore, acute inflammation in the context of 
bacterial sepsis is one of the highest causes of mortality in the United States. For this 
reason, research into the modulators of inflammation is important to uncovering novel 
drug targets for anti-inflammatory therapies. In this study, we chose to determine the 
functional relevance of GSK3 inhibition by using a mouse model of lethal 
endotoxemia. This model involves injection of mice with high levels of LPS, which 
induces a lethal cytokine storm.  Our results indicate that GSK3β inhibition has an anti-
inflammatory effect in vivo. These data are supported by multiple studies showing a 
protective effect of direct treatment with GSK3 inhibitors on LPS endotoxemia195,196. 
Our results go further to suggest that it is the effect of GSK3 inhibition in macrophages 
specifically that is responsible for this protective effect. 
4.6 Conclusion 
In sum, our studies reveal the generation of an anti-inflammatory and pro-
healing phenotype in activated human macrophages when stimulated with Fc-receptor 





biomarkers suitable for identification of this phenotype using RNAscope technology, 
whereas DC-STAMP could be used as a marker in flow cytometry applications. The 
anti-inflammatory phenotype observed at the transcript level was also found to translate 
to the protein level, where IL-10, activin A, and MMP-1 serve as high-abundance 
ELISA markers for R-M-IC. The gene changes observed appeared to be induced at 
least partially by activation of Akt and ERK. GSK3, which is downstream of Akt 
signaling, is inhibited by blocking of nuclear translocation by treatment with immune 
complexes. Since inhibition of GSK3 phenocopies the effects of immune complex on 
upregulated markers, it is suggested that GSK3 plays a role in the generation of this 
phenotype. Macrophages treated with LPS and a GSK3 inhibitor protected mice from 
lethal endotoxemia. Given the significance of macrophage activation in both chronic 
and infectious diseases, we hope that these studies will facilitate clinical and 
pathological research in humans to determine the role of macrophage phenotypes in 
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